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I. INTRODUCTION
1 
 The oral route of drug administration is the most important method of administrating 
drugs for systemic effects. Oral drug delivery has been known for decades as the most widely 
utilized route among all the routes that have been employed for the systemic delivery of drug 
via various pharmaceutical products of different dosage forms. The reasons that the oral route 
achieved such popularity may be in part attributed to its ease of administration, belief that by 
oral administration of   the drug is well absorbed. 
 All the pharmaceutical products formulated for systemic delivery via the oral route of 
administration irrespective of the mode of delivery (immediate, sustained or controlled 
release) and the design of dosage forms (either solid dispersion (or) liquid), must be 
developed within the intrinsic characteristics of GI physiology, pharmacokinetics, 
pharmacodynamics and formulation design to achieve a systemic approach to the successful 
development of an oral pharmaceutical dosage form.   
1.1  TABLETS
 
Tablets are solid dosage forms each containing a unit dose of one or more 
medicaments. They are intended for oral administration. Some tablets are swallowed whole 
or after being chewed, some are dissolved or dispersed in water before administration and 
some are retained in the mouth where the active ingredient is liberated. 
Tablets are used mainly for systemic drug delivery but also for local drug action. For 
systemic use, the drug must release from the tablet by normally dissolving in the fluids of the 
mouth, stomach or intestine and thereafter be absorbed into the systemic circulation. Because 
of their composition, method of manufacture or intended use, tablets present a variety of 
characteristics and consequently there are several categories of tablets.  
Tablets are usually solid, right circular cylinders, the end surfaces of which are flat or convex 
and the edges of which may be beveled. They may exist in other shapes like triangular, 
rectangular, etc also. They may have lines or break-marks and may bear a symbol or other 
markings. They are sufficiently hard to withstand handling without crumbling or breaking. 
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TABLET PROPERTIES         
 Tablet should be elegant product having its own identity while being free of defects 
such as capping, cracks, discoloration and any other contamination. 
 Tablets should have the strength to withstand the rigors of mechanical shocks 
encountered in its production, packaging, shipping, dispensing and handling. 
 Tablets should have chemical and physical stability to maintain its physical attributes 
over time. 
 Tablets should be able to release the active ingredient in the body in a predictable and 
reproducible manner. 
 Tablets must have a suitable chemical stability over time so as not to allow any 
degradation or alteration of the active moiety.  
ADVANTAGES OF TABLETS
 
 Tablet is orally administered non invasive unit dosage form, and also has the greatest 
dose precision when self medication is considered which makes it the most popular 
formulation among the patients. 
 They may provide the greatest ease of swallowing with the least tendency for “hang – 
up” above the stomach, especially when coated, provided that tablet disintegration is 
not excessively rapid. 
 Tablets are the easiest and most economical to pack and ship as compared to other 
oral dosage forms. 
 Product identification is simple by using punches of different shapes or some 
embossing on the punches. 
 Tablets are better suited for large- scale production than other unit dosage forms. 
 Tablets lend themselves to certain special release profile products. Such as enteric or 
delayed release products. 
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 Tablets have the best - combined properties of chemical, mechanical and 
microbiological stability as compared to other oral forms. 
 Tablets are the maximum profit making when reviewed through pharmaceutical 
company’ perspective. 
DISADVANTAGES OF TABLETS: 
 When the dose of the drug is large, tablets might be too big for children or even adults   
to swallow. 
 When the drugs need to act very fast, the disintegration of the tablet and the 
dissolution of the tablet might be the rate- limiting step in determining the onset of 
drug action. 
 Compression can change the physical properties, particle size and crystal form of the 
drug can affect the proper action after administration. 
 Sometimes the physical and chemical properties of the drug make it difficult to 
overcome compression problems such as capping, lamination, picking and sticking. 
1.2.  ADDITIVES USED IN TABLETS
2  
  
Ingredients in a tablet other than the active ingredient are called excipients. Excipients 
can help powders become more fluid. This fluid motion is very important for transferring 
powders into the die cavity for compaction. Excipients are used not only to enhance the 
performance of active ingredients, but also to simply make the active ingredients work better 
on the tablet press. 
 In the pharmaceutical industry it is a catch all term which includes such groups comprising 
diluents or fillers, binder or adhesives, disintegrants, lubricants, glidants or flow promoters, 
colors, flavours, fragrances, and sweeteners. All of these must meet certain criteria as 
follows. 
 They must be physiologically inert. 
 They must be physically and chemically stable. 
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 They must be free of any bacteria considered to be pathogenic or otherwise 
objectionable. 
 They must not interfere with the bioavailability of the drug. 
 They should be commercially available in form and purity commensurate to 
pharmaceutical standards. 
 For drug products that are classified as food, such as vitamins, other dietary aids, and 
so on, the excipients must be approved as food additives. 
 Cost must be relatively inexpensive. 
 They must conform to all current regulatory requirements. 
Diluents: 
Diluents are fillers designed to make up the required bulk of the tablet when the drug 
dosage itself is inadequate to produce this bulk. Since combinations are also a possibility, 
consideration should be given to possible mixture. 
 Eg: Lactose, calcium carbonate, calcium phosphate, calcium sulphate, calcium dihydrate, 
Dibasic calcium phosphate, starch, dextrose, mannitol. 
 Disintegrants: 
  Disintegrants is the term applied to various agents added to the tablet granulation for 
the purpose of causing the compressed tablet to break apart (disintegrate) when placed in an 
aqueous environment. Disintegrants constitute a group of materials that, on contact with 
water, swell, hydrate, change in volume or form, or react chemically to produce disruptive 
changes in the tablet.  
Eg. Micro crystalline cellulose, Starch, Croscarmellose sodium, Sodium starch glycolate, 
Methyl cellulose, Sodium carboxy methyl cellulose. 
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Binders: 
 Binders are the “glue” that hold powders together to form granules. They are 
adhesives that are added to the tablet formulations to provide the cohesiveness required for 
the bonding together of the granules under compaction to form the tablet. Binders are added 
either dry or in liquid form during wet granulation to form granules or to promote cohesive 
compacts for directly compressed tablets.  
Eg. Starch, Povidone, Acacia, Gelatin, Tragacanth. 
Lubricants: 
Lubricants are used in the tablet formulations to ease the ejection of the tablet from 
the die, to prevent sticking of tablets to the punches, and to prevent excessive wear on 
punches and dies. Lubricants should be carefully selected for efficiency and for the properties 
of the tablet formulation. 
 Eg: Stearic acid, talc, silica and boric acid. 
Anti adherents: 
Anti adherents have the purpose of reducing sticking or adhesion of any of the tablet 
granulation or powder to the faces of the punches or to the die wall.  
Eg: Magnesium stearate, talc and starch. 
Glidants: 
Glidants are materials that improve the flow characteristics of granulations by 
reducing interparticulate friction. They increase the flow of materials from larger to smaller 
apertures, from the hopper into the die cavities of the tablet press.  
Eg: Talc, starch and silica. 
  
INTRODUCTION 
 
 Page 6 
 
Absorbents: 
Absorbents are substances that are capable of holding quantities of fluid in an 
apparently dry state. Oil soluble drugs, fluid extracts or oil can be mixed with absorbent and 
then granulated and compressed into the tablets.  
Eg: Fumed silica, microcrystalline cellulose, magnesium carbonate. 
 
Coloring agents: 
Coloring agents are incorporated into tablet generally for one or more of three 
purposes. First, colors may be used for product identification, production of a more elegant 
product and the continual decertification of many synthetic dyes. All colorants used in 
pharmaceutical must be approved and certified by the FDA. Two forms of color have 
typically been used in tablet preparation. These are the FD&C and D&C dyes. 
Eg: Erythrosine, carmine and Quinoline yellow lake. 
Flavouring agents: 
Flavouring agents are incorporated into the formulation to give the tablet a more 
pleasant flavour or mask an unpleasant one. Aqueous (water soluble) flavours have found 
little acceptance due to their lesser stability upon aging.   
Eg: Chocolate, peppermint and vanilla. 
Sweetning agents:     
Sweeteners are added primarily to chewable tablets when the commonly used carriers 
such as mannitol, lactose, sucrose, and dextrose do not sufficiently mask the taste of the 
components.  
Eg: Saccharin, sucrose and aspartame. 
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1.3  TYPES OF TABLETS
3 
1.3.1 BASED ON ROUTE OF ADMINISTRATION: 
      I.  Oral tablets for ingestion. 
      II. Tablets used in the oral cavity 
III. Tablets administered by other routes. 
IV. Tablets used to prepare solutions 
I.  ORAL TABLETS FOR INGESTION: 
 Compressed tablets, multiple compressed tablets 
 Layered tablets, compression coated tablets 
 Repeat action tablets  
 Delayed action and enteric coated tablets 
 Sugar and chocolate coated tablets 
 Film coated tablets 
 Chewable tablets 
II. TABLETS USED IN THE ORAL CAVITY: 
 Buccal  tablets 
 Sublingual tablets 
 Troches and lozenges  Dental cones 
III. TABLETS ADMINISTERED BY OTHER ROUTES: 
  Implantation tablets 
   Vaginal tablets   
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IV. TABLETS USED TO PREPARE SOLUTION 
  Effervescent tablets 
   Dispensing tablets     
   Hypodermic tablets 
   Tablet triturates 
I. TABLETS INGESTED ORALLY 
         Orally ingested tablets are designed to be swallowed intact, with the exception of 
chewable tablets. 
A) COMPRESSED TABLETS OR STANDARD COMPRESSED TABLETS: 
         Compressed tablets are prepared by a single compression, occur in various shapes and 
sizes and usually contain in addition to the medicinal substances, a number of pharmaceutical 
adjuncts including Binders, which help powders fuse or link particles to one another. Fillers, 
which bulk up a tablet. Lubricants, which prevent powders from sticking to the metal 
components of the tablet press and tablet – press tooling. Disintegrants that break up the 
tablet after being ingested. Several other excipients can be added to a formula to improve 
flow, compression, hardness, taste and tablet performance. 
B) MULTIPLE COMPRESSED TABLETS: 
         Multiple compressed tablets are prepared by subjecting the fill material to more than a 
single compression. There are two classes of multiple compressed tablets.  
 Layered tablets 
 Compression-coated tablets 
         Both types may be either two-component or three component systems: two-or three –
layer tablets, a tablet within a tablet, or a tablet within a tablet, within a tablet.  
Both types of tablets usually undergo a light compression as each component is laid down, 
with the main compression being the final one. Tablets in this category are usually prepared 
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for one of the two reasons: to separate physically or chemically incompatible ingredients or to 
produce repeat-action or prolonged action products. In preparation of tablets within tablets, 
special machines are required to place the preformed core tablet precisely within the die for 
application of surrounding fill material. 
C)  REPEAT-ACTION TABLETS: 
 In Repeat-Action Tablets the core tablet is usually coated with shellac or an enteric 
polymer so that it will not release its drug load in the stomach. The second dose of drug is 
then added in the sugar coating, either in solution in the syrup or as a part of the dusting 
powder added for rapid coat builds up.  
D) DELAYED-ACTION AND ENTERIC COATED TABLETS: 
The delayed-action tablet dosage form is intended to release a drug after some time 
delay, or after the tablet has passed through one part of the GI tract into another.   The enteric 
coated tablet is the most common example of a delayed-action tablet product. Enteric coated 
tablets are tablets with a coating that resist dissolution or disruption in the stomach but not in 
the intestine, thereby allowing for tablet transit through the stomach in favour of tablet 
disintegration, drug dissolution and absorption from the intestines. 
         Enteric coatings are employed when the drug substance is destroyed by gastric acid or 
is particularly irritating to the gastric mucosa or when bypass of the stomach substantially 
enhances drug absorption. 
E) SUGAR AND CHOCOLATE-COATED TABLETS 
 Compressed tablets may be coated with a colored or uncolored sugar layer. The coating 
is water soluble and quickly dissolves after swallowing. The sugar-coat protects the enclosed 
drug from the environment and provides a barrier to objectionable taste or odor. The sugar 
coat also enhances the appearance of the compressed tablet and permits imprinting of 
identifying manufacturer’s information. Sugar coating may add 50% of the weight and bulk 
of the uncoated tablet.  Chocolate coated tablets are nearly a thing of the past. They are too 
easily mistaken for candy by children. 
F) FILM COATED TABLETS: 
         Film coated tablets are compressed tablets coated with a thin layer of polymer capable 
of forming a skin like film. The film is usually coloured and it is more durable, less bulky, 
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and less time consuming to apply than sugar coatings. The coating is designed to rupture and 
expose the core tablet at the desired location in the gastrointestinal tract. Film coating can 
protect the tablet from light, temperature and moisture, mask undesirable taste or odor, 
improve the appearance, provide tablet identity, facilitate swallowing and control or modify 
the release of the drug. 
G) CHEWABLE TABLETS: 
         Chewable tablets are intended to be chewed in the mouth prior to swallowing and are 
not intended to be swallowed intact.  The purpose of the chewable tablet is to provide a unit 
dosage form of medication which can be easily administered to infants and children or to the 
elderly, who may have difficulty swallowing a tablet intact. The chewable tablet offers two 
major advantages to the delivery of a solid antacid dosage form. First, the dose of most 
antacids is large, so that the typical antacid tablet would be large to swallow, second the 
activity of an antacid is related to particle size. 
II) TABLETS USED IN THE ORAL CAVITY 
A) BUCCAL AND SUBLINGUAL TABLETS: 
         These two classes of tablets are intended to held in the mouth. Buccal and sublingual 
tablets are flat oval tablets intended to be dissolved in the buccal pouch (buccal tablets) or 
beneath the tongue (sublingual tablets) for absorption through the oral mucosa. Buccal tablets 
are designed to erode, slowly whereas for sublingual use (such as nitro-glycerine) dissolve 
promptly and provide rapid drug effects. Buccal and sublingual tablets dissolve slowly 
typically over a 15-30 minutes period, to provide for a effective absorption. 
B) TROCHES AND LOZENGES: 
         These are two other types of tablets used in the oral cavity. Troches are designed to 
deliver medications directly to the mucus membranes of the mouth by dissolving slowly 
when placed between the tongue and gums. Troches are defined as a small medicated lozenge 
to exert a local effect in the mouth or throat. Lozenges can also be placed under the tongue 
and allowed to dissolve for sublingual delivery. This allows the medication to enter the blood 
stream quickly and easily. Lozenges can be enhanced with natural sweeteners. These tablet 
forms are commonly used to treat sore throat or to control coughing in the common cold. 
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C) DENTAL CONES: 
         Dental cones are relatively minor tablet forms that are designed to be placed in the 
empty socket following a tooth extraction. Their usual purpose is to prevent the 
multiplication of bacteria in the socket following extraction by employing a slow releasing 
Antibacterial Compound or to reduce bleeding by containing an astringent or coagulant. 
III) TABLETS ADMINISTERED BY OTHER ROUTES 
A) IMPLANTATION TABLETS: 
         Implantation or depot tablets are designed for subcutaneous implantation in animals or 
man. Their purpose is to provide prolonged drug effects ranging from one month to a year. 
They are usually designed to provide a constant drug release rate as possible. These tablets 
are usually small, cylindric, or rosette shaped and is typically not more than 8mm in length. 
B) VAGINAL TABLETS: 
         Vaginal tablets or inserts are designed to undergo slow dissolution and drug release in 
the vaginal cavity. The tablets are usually ovoid or pear shaped to facilitate retention in the 
vagina. This tablet form is used to release antibacterial agents, antiseptics or astringent to 
treat vaginal infections. 
IV) TABLETS USED TO PREPARE SOLUTION 
A) EFFERVESCENT TABLETS: 
         Effervescent tablets are designed to produce a solution rapidly with the simultaneous 
release of carbon dioxide. The tablets are typically prepared by compressing the active 
ingredients with mixtures of organic acids – such as citric acid or tartaric acid and sodium 
bicarbonate. When such tablets is dropped into a glass of water, a chemical reaction is 
initiated between the acid and the sodium bicarbonate to form the sodium salt of acid, and to 
produce carbon dioxide and water. These tablets generally contain medicinal substances that 
dissolve rapidly when added to water. The reaction is quite rapid and is usually completed 
within one minute or less. In addition to having the capability of producing clear solutions, 
such tablets produce a pleasantly flavored carbonated drink, which assists in masking the 
taste of certain drugs. 
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B) DISPENSING TABLETS: 
         Dispensing tablets are also called as compounding tablets because the pharmacist used 
them to compound prescriptions. The tablets contains large amount of highly potent drug 
substances, so that pharmacist could rapidly obtain premeasured amounts for compounding 
multiple dosage units. Materials such as mild silver proteinate, bichlorides of mercury, 
merbromin and quaternary ammonium compounds are used to prepare the dispensing tablets. 
C) HYPODERMIC TABLETS: 
         Hypodermic tablets are composed of one or more drugs with other readily water soluble 
ingredients and are intended to be added to sterile water or water for injection. They were 
originally used by physicians in extemporaneous preparation of parenteral solutions. 
D) TABLET TRITURATES:  
         Tablet triturates are small, usually cylindric, molded or compressed tablets. The drugs 
employed in such products were usually quite potent and were mixed with lactose possibly a 
binder, such as powder acacia, after which the mixture was moistened to produce a moldable, 
compactable mass. This mass was forced into holes of a mold board fabricated from wood or 
plastic, after which the tablet were ejected using pegboard, whose pegs matched the holes in 
the mold. The tablets were then allowed to dry.  Alcohol was commonly used to make wet 
powder mass. 
1.4. TABLET MANUFACTURING PROCESS:
4 
A tablet with good characteristics is not made on a tablet press; it is made in the 
granulation process. Joined particles within a given granulation process will improve flow 
and compression characteristics, reduce segregation, improve content uniformity, and 
eliminate excessive amounts of fine particles. The results will be improved yields, reduced 
tablet defects, increased productivity and reduced down time. The objective of the process is 
to combine ingredients to produce a quality tablet. 
GRANULATION
 
         Granulation is the processes of collecting particles together by creating bonds between 
them. Bonds are formed by compression or by using a binding agent. The granulation process 
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combines one or more powders and forms a granule that will allow tableting process to be 
predictable and will produce quality tablets within the required tablet-press speed range. 
A tablet formulation contains several ingredients apart from the active ingredient. The 
remaining ingredients are necessary because a suitable tablet cannot be composed of active 
ingredient alone. The tablet may require variations such as additional bulk, improved flow, 
better compressibility, flavoring, improved disintegration characteristics or enhanced 
appearance. 
If the active ingredients in a formulation represent a very small portion of the overall 
tablet, then the challenge is to ensure that each tablet has the same amount of active 
ingredients.  Sometimes, blending the ingredients is not enough. The active ingredients may 
segregate from the other ingredients in the blending process. The ingredients may be 
incompatible because of particle size, particle density, flow characteristics, compressibility 
and moisture content. These incompatibilities can cause problems such as segregation during 
blending or during transfer of the product to the press as well as separation of the active 
ingredients on the tablet press. 
Granulating the active ingredient by itself and then blending it with the rest of the 
ingredients is one solution to the segregation problem or most of the ingredients could be 
granulated together. The best course of action to ensure that each tablet contains the correct 
amount of active ingredient, especially if the active is only  a small percentage of the tablet 
ingredients, is to mix the active ingredients thoroughly with some or most of the other 
ingredients and then granulate the blend (i.e., from the blend into granules). Each granule 
would contain a little of each of the ingredients, and the active ingredient would be 
distributed evenly throughout the blend. 
         Three basic techniques are used to prepare powders for compression into a tablet 
 Direct compression. 
 Wet granulation 
  Dry granulation. 
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WET GRANULATION:
5 
         When powders are very fine, fluffy, will not stay blended, or will not compress, then 
they must be granulated. Wet granulation, the process of adding a liquid solution to powders, 
is one of the common ways to granulate. The process can be very simple or complex 
depending on the characteristics of the powders, the final objective of tablet making, and the 
availability of equipment.  
Method: 
Weighing and blending the ingredients: specified quantities of active ingredients, 
diluents or filler, and disintegrating agent are mixed by mechanical powder blend until 
uniform. A liquid binder is added to the powder mixture to facilitate adhesion of the powder 
until a damp mass resembling dough is formed. The wet mass is passed through a screen to 
prepare the granules. This may be done by hand or with special equipment. Granules may be 
dried in thermostatically controlled ovens that constantly record the time, temperature and 
humidity. After drying the granules are passed through a screen of a smaller mesh than that 
used to prepare the original granulation. Sizing of the granules are necessary so that the die 
cavities for tablet compression may be completely and rapidly filled by the free flowing 
granulation and fines should be added with this granules because void or air spaces left by too 
large a granulation result in production of uneven tablets. After dry screening, a dry lubricant 
is dusted over the spread out granulation through a fine mesh screen. After this process the 
granules were compressed into tablets. 
DRY GRANULATION:
6 
The dry granulation process is used to form granules without using a liquid solution 
because the product to be granulated may be sensitive to moisture and heat. Forming granules 
without moisture requires compacting and densifying the powders. When a tablet press is 
used for tablet granulation, the powders may not possess enough natural flow to feed the 
product uniformly into the die cavity, resulting in varying degrees of densification. After 
weighing and mixing the ingredients, the powder mixture is slugged, or compressed into 
large flat tablets or pellets about 1 inch in diameter. The slugs are broken up by hand or by 
mill and passed through a screen and tablets are prepared by compression. 
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The roller compactor uses an auger-feed system that will consistently deliver powder 
uniformly between two pressure rollers. The powders are compacted into a ribbon or small 
pellets between these rollers and milled through a low – shear mill. When the product is 
compacted properly, then it can be passed through a mill and final being the compression into 
tablets. Roller compaction or dry granulation equipment offers a wide range of pressures and 
roll types to attain proper densification. 
DIRECT COMPRESSION:
7 
Crystalline substances, such as sodium chloride, sodium bromide and potassium 
chloride may be compressed directly without the need of granulation since the above 
chemicals have free flowing and cohesive properties. For chemicals lacking this quality, 
special pharmaceutical excipients may be used to impart the necessary qualities for 
production of tablet by direct compression. As heat and water are not involved in direct 
compression method product stability can be improved. The capping, splitting, or lamination 
of tablets is sometimes related to air entrapment during direct compression. Forced or 
induced feeders can reduce air entrapment, making the fill powder more dense and suitable 
for compaction. 
1.5 COATING:
8 
Coating is a process by which an essentially dry, outer layer of coating material is 
applied to the surface of a dosage form in order to confer specific benefits that broadly range 
from facilitating product identification to modifying drug release from the dosage form. The 
application of coating to tablets, which is an additional step in the manufacturing process, 
increases the cost of the product; therefore, the decision to coat a tablet is usually based on 
one or more of the following objectives.   
 To mask the taste, odor or color of the drug. 
 To provide physical and chemical protection for the drug. 
 To control the release of the drug from the tablet. 
 To protect the drug from the gastric environment of the stomach with an acid resistant 
enteric coating. 
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 To improve the pharmaceutical elegance by use of special colors & contrasting 
printing. 
The general methods involved in coating of tablets are as follows: 
I. FILM COATING: 
Film coating is applied as a thin polymeric film to the surface of a tablet. Film coating 
can protect the tablet from light, temperature and moisture, mask undesirable taste or odor, 
improve the appearance, provide tablet identity, facilitate swallowing and control or modify 
the release of the drug.
20
 Film coating solutions may be aqueous or non- aqueous. 
FILM FORMER:
9 
A film former should be capable of producing smooth, thin films reproducible under 
conventional coating condition and applicable to a variety of tablet shapes. It should maintain 
the film strength and minimizes film cracking during handling or subsequent storage. 
Film coating formulations usually contain the following components 
      1.Polymer  
      2.Plasticizer  
      3.Colorants/Opacifiers 
      4.Solvent/Vehicle 
      5.Flavoursandsweeteners  
     6.Surfactants  
     7.Antioxidants 
     8. Antimicrobials/Preservatives 
They are explained below, 
1) POLYMERS 
   A film former capable of producing smooth thin films reproducible under the 
prescribed coating conditions. Amongst the vast majority of the polymers used in film 
coating are cellulose derivatives or acrylic polymers and copolymers. 
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A) Immediate Release Coating Polymers 
a) Cellulose derivates:  
  The most widely used of cellulosic polymers is HPMC (Hydroxypropyl Methyl 
Cellulose). It is readily soluble in aqueous media, forms film with good mechanical 
properties (strength, flexibility and adhesion to the tablet core).  
Other examples: MC (Methyl Cellulose) & HPC (Hydroxypropyl Cellulose),  
 Hydroxyl Propyl Methyl Cellulose: The polymer is prepared by reacting alkali 
treated cellulose first with methyl chloride to introduce methoxy groups and then with 
propylene oxide to introduce propylene glycol ether group. Hydroxy Propyl methyl 
cellulose closely approaches the desired attributes of an ideal polymer for film 
coating. 
 Methyl Hydroxy Ethyl Cellulose: This polymer is prepared by reacting alkali treated 
cellulose first with methyl chloride and then with ethylene oxide. A wide variety of 
viscosity grades are available. It is structurally similar to Hydroxyl Propyl Methyl 
Cellulose. It is soluble in fewer organic solvents. 
 Ethylcellulose: Ethylcellulose is manufactured by the reaction of ethyl chloride or 
ethyl sulfate with cellulose dissolved in sodium hydroxide. This material is 
completely in soluble in water & gastrointestinal fluids, and thus cannot be used alone 
for tablet coating. It is usually combined with other water soluble polymers to prepare 
films with reduced water soluble properties. 
 Hydroxypropyl cellulose: Hydroxypropyl cellulose is manufactured by treatment of 
cellulose with sodium hydroxide, followed by a reaction with propylene oxide at an 
elevated temperature and pressure. It is soluble in water below 40° C, gastrointestinal 
fluids and many polar organic solvents.   
 Sodium Carboxy Methyl Cellulose: Sodium Carboxy Methyl Cellulose is sodium 
salt of carboxy methyl cellulose and is manufactured by the reaction of soda cellulose 
with the sodium salt of monochloro acetic acid. It is available in low, medium, high 
and extra high viscosity grades. It is easily dispersed in water to form colloidal 
solution but insoluble in most organic solvents. 
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b). Vinyl derivatives  
The most widely used vinyl polymer derivate is PVP. It has a limited use in film 
coating because of its inherent tackiness. A copolymer of PVP and vinyl acetate forms better 
films. 
Povidone: Povidone is a synthetic polymer consisting of linear 1-vinyl-2-
pyrolidinone groups. Povidone is available in various grades. The most common uses of 
povidone in pharmaceuticals is as a tablet binder and tablet coating material. 
c). Polyethylene glycols: 
 Polyethylene glycols are manufactured by the reaction of ethylene glycol with 
ethylene oxide in the presence of sodium hydroxide at elevated temperature and under 
pressure. The materials with low molecular weights(200-600) are liquids at room temperature 
and are used as plasticizer for coating solution films.  
d). Acrylate polymer: 
Acrylate polymers are available only as organic solution and solid materials. These 
polymers produce films for the delayed action preparation similar to ethyl cellulose 
formulation. 
B) Modified Release Coating Polymers 
a) Extended release coating polymers 
They are dissolved in organic solvent or dispersed in aqueous medium. Cellulose 
derivates also often used. Cellulose derivates are highly substituted cellulosic ether, thus 
rendering the polymer water-insoluble. 
Example: Ethylcellulose. 
b) Enteric Coating Polymers 
An enteric coat is designed to resist the low pH of gastric fluids but to disrupt or 
dissolve when the tablet enters the higher pH of the duodenum. The important reasons for 
enteric coating are as follows;  
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 To protect acid-labile drugs form the gastric fluid.  
 To prevent gastric distress or nausea due to irritation from a drug. 
 To deliver drugs intended for local action in the intestines. 
 To deliver drugs that are optimally absorbed in the small intestines to 
their primary absorption site in their most concentrated form. 
 To provide a delayed- release component for repeat action tablet. 
i) Phthalate derivative: 
 Cellulose acetate phthalate (CAP): It has been widely used in the industry. It is also 
hygroscopic and relatively permeable to moisture and gastric fluids in comparison 
with some other enteric polymers. It dissolves only above pH 6. CAP films are brittle 
and usually formulated with hydrophobic film forming materials or adjuvants to 
achieve a better enteric film. 
 Hydroxypropyl methylcellulose phthalate: They are derived from hydroxy propyl 
methylcellulose by esterification with phthalic anhydride. These polymers dissolve at 
a low pH (at 5 to 5.5) than CAP or acrylic co polymers, and this solubility 
characteristic may result in higher bioavailability of some specific drugs. 
 Polyvinyl acetate phthalate :( PVAP) Polyvinyl acetate phthalate is manufactured 
by the esterification of a partially hydrolyzed polyvinyl acetate with phthalic 
anhydride. This polymer is similar to Hydroxypropyl methylcellulose phthalate in 
stability and pH dependent solubility.   
ii) Acrylate derivative: 
 Acrylate polymers: Two forms of commercially available enteric acrylic resins are 
Eudragit L and Eudragit S. Both resins produce films that are resistant to gastric fluid 
and are soluble in the intestinal fluids at  pH at 6 and 7 respectively. 
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2) SURFACTANTS 
Surfactants because of their chemical structure have tendency to accumulate at the 
boundary between two phases. They lower the interfacial tension between oil and water 
phases and also enhance the spreadability of the film during application. Eg: spans, tweens. 
3) PLASTICIZERS 
Affords flexibility and elasticity to the coat and thus provide durability.  
Plasticizers are simply relatively low molecular weight materials which have the capacity to 
alter the physical properties of the polymer to render it more useful in performing its function 
as a film coating material. It is generally considered to be mechanism of plasticizer molecules 
to interpose themselves between individual polymer strands thus breaking down polymer-
polymer interactions. Thus polymer is converted in to more pliable materials.  
Plastisizers are classifying in three groups. Polyos types contain glycerol, propylene glycol, 
PEG (Polyethylene glycol). Organic esters contain phthalate esters, dibutyl sebacete, citrate 
esters, triacetin. Oils/glycerides contain castor oil, acetylated, monoglycerides, fractionated 
coconut oil. 
4) SOLVENTS/VEHICLES  
The key function of a solvent system is to dissolve or disperse the polymers and other 
additives. Volatile organic solvents may be used to allow good spreadability of the coat 
components over the tablet and allowing rapid evaporation, but they are expensive and show 
environmental hazards and solvent residue in the formulation must be investigated (certain 
limit). Aqueous vehicles are safer, but they show slower evaporation and may affect drug 
stability.All major manufactures of polymers for coating give basic physicochemical data on 
their polymers. These data are usually helpful to a formulator. 
The major classes of solvents being used are, 
 a. Water 
 b.Chlorinatedhydrocarbons 
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5) COLORANTS/OPACQUANTS  
Provides an elegant appearance. Ex.: Iron, oxide, pigment, Titanium dioxide and 
Aluminum lakes. Identification of the product by the manufacturer and therefore act as an aid 
for existing GMP procedures.  
 Reinforcement of brand imaging and reduction in product counterfeiting.  
 Identification of the product by patients by using colourants. 
Colorants for film coating are having, in more or less amount, property of opacifier. So they 
would give protection to active ingredients in presence of light. Colorants are mainly 
classified in to three parts. Sunset yellow, tartrazine, erythrosine are examples of Organic 
dyes and their lakes. Iron oxide yellow, red and black, titanium dioxide, talc are the examples 
of Inorganic colours. Anthrocyanins, ribofloavine and carmine are the examples of natural 
colours. 
 
6) FLAVORS AND SWEETENERS are added to mask unpleasant odours or to develop the 
desired taste. For example, aspartame, various fruit spirits (organic solvent), water soluble 
pineapple flavour (aqueous solvent) etc. 
7) ANTIOXIDANTS are incorporated to stabilize a dye system to oxidation and colour 
change. For example oximes, phenols etc. 
8) ANTIMICROBIALS/PRESERVATIVES are added to put off microbial growth in the 
coating composition. Some aqueous cellulosic coating solutions are mainly prone to 
microbial growth, and long-lasting storage of the coating composition should be avoided. For 
example alkylisothiazloinone, carbamates, benzothiazoles etc. 
II. SUGAR COATING: 
Sugar coating serves the various purposes of protecting the drug from the air and 
humidity and providing a taste or a smell barrier to objectional tasting and smelling drug. 
Sugar coating is a multistep process.
 
Tablets intended to be coated are manufactured to be 
thin edged and highly convex to allow the coatings to form rounded rather than angular 
edges. The sugar coating of tablets may be divided into the following steps: 
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1) SEAL COATING:  Seal coat is necessary to protect the tablet core from the aqueous 
nature of sucrose application. Sealing also prevents certain types of materials from 
migrating to the surface tablets and spoiling the appearance. Shellac is used as water 
impervious polymer. Shellac is insoluble in water but shows solubility in aqueous 
alkalis, it is moderately soluble in warm ethanol. The application of sealant is 
followed by an application of dusting powder to prevent tackiness.  
2) SUB COATING: During the sugar coating process the increase in the weight 
achieved can be 30 – 50% of the weight of the original tablet core. Much of the added 
weight is applied at the sub coating stage. Sub coating serves the confer on the tablet 
core a perfectly rounded aspect. A sub coating suspension containing both the binder 
and the insoluble powder is sprayed intermittently on the tablet bed. The product at 
the end of the sub coating will be too rough to continue with color coating. 
3) SMOOTHING AND FINAL ROUNDING: After the tablets are sub coated, 5 to 10 
additional coatings of thick syrup are applied to complete the rounding and smooth 
the coatings. This syrup is sucrose based, with or without additional components such 
as starch and calcium carbonate. 
4) FINISHING AND COLORING: To attain final smoothness and the appropriate 
color to the tablets, several coats of thin syrup containing the desired colorants are 
applied in the usual manner. This step is performed in a clean pan, free from previous 
coating materials. 
5)  POLISHING: After the coloring process the tablet have a somewhat dull 
appearance which requires a separate polishing step to give them the high degree of 
gloss traditionally associated with sugar coated tablets. Application of an organic 
solvent/ suspension of waxes e.g beeswax or carnauba is generally used. 
1.5. QUALITY CONTROL PARAMETERS:
10 
1.5.1. GRANULES CHARACTERISTICS: 
 Flowability:  
       Press speed requires powders to be very fluid, a property commonly referred to as 
product flow ability. Good flow characteristics are necessary because the mechanical action 
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of the tablet press requires a volume of fill. A tablet press does not weigh the precise amount 
of powder for each tablet. To achieve consistent tablet weights, the tablet press must be 
designed to flow consistently and to fill volumetrically. Thus the granules (or powders, for 
direct compression) must possess a consistent particle- size distribution and density to attain 
proper flow and achieve volume of fill.  In other words, the powders must flow consistently 
to attain consistent results. 
 Compressibility:11 
A powder with a high compressibility forms tablets with a high resistance towards 
fracturing and without tendencies to cap or laminate. In practice, the most common way to 
assess powder compressibility is to study the effect of compression pressure on the strength 
of the resulting tablet. Compressing a tablet of many different powders that have varying 
physical characteristics can be difficult. If the formula has some of both characteristics -large 
particles with high moisture content and small, dry particles- then the tablet may or may not 
compress well and probably will have difficulty holding together. One of the main reasons to 
granulate powders is to make them more compressible. 
 Bulk density and tapped density: 
Bulk density is determined by measuring the volume of a known mass of powder sample 
that has been passed through a screen into a graduated cylinder or through a volume 
measuring apparatus into a cup. The bulk density often is the bulk density of the powder as 
poured or as passively filled into a measuring vessel. Because the interparticulate interactions 
that influence the bulking properties of a powder are also the interactions that interfere with 
powder flow, a comparison of the bulk and tapped densities can give a measure of the relative 
importance of these interactions in a given powder. Such a comparison is often used as an 
index of the ability of the powder to flow. 
 Tapped density: 
It is achieved by mechanically tapping a measuring cylinder containing a powder sample. 
After observing the initial volume the cylinder is mechanically tapped, and volume readings 
are taken until further volume has not changed. Mechanical tapping is achieved by raising the 
cylinder and allowing it to drop under its own weight. 
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1.5.2. COMPRESSED TABLET CHARACTERISTICS:
12 
 General appearance: 
The general appearance of the tablet, its visual identity and overall “elegance” is essential 
for consumer acceptance, for control of uniformity in tablet lot and for monitoring trouble 
free manufacturing. It involves monitoring different attributes like tablet’s shape, size, color, 
presence or absence of odor, taste, surface texture, physical flaws, consistency, and legibility 
of any identifying markings. 
 Tablet thickness:  
The thickness of a tablet is determined by the diameter of the die, the amount of fill 
permitted to enter the die, the compaction characteristics of the fill material, and the force or 
pressure applied during compression. Tablet thickness is measured with a caliper or thickness 
gauge which measures the thickness in millimeters. 
 Tablet hardness:  
The resistance of the tablet to chipping, abrasion or breaking under conditions of storage, 
transportation and handling before usage depends on its hardness. A hardness tester measures 
the force required to break the tablet when the force generated by a spring is applied 
diametrically to the tablet. Hardness (crushing strength) determinations are made throughout 
the tablet runs to determine the need for pressure adjustments on the tableting machine. If the 
tablet is too hard, it may not disintegrate in the required time period or meet the dissolution 
specification. 
 Tablet friability:  
  The term friability is the ability of the tablet to withstand abrasion in packaging, 
handling and shipping. In a friablator, a number of tablets are weighed and placed in the 
tumbling apparatus where they are exposed to rolling and repeated shocks resulting from 
freefalls within the apparatus. After a given number of rotations the tablets are weighed and 
the loss in weight indicates the ability of the tablets to withstand this type of wear. 
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 Weight variation:  
The volumetric fill of the die cavity determines the weight of the compressed tablet. 
In setting up the tablet machine the fill is adjusted to give the desired tablet weight. The 
weight of the tablet is the quantity of the granulation which contains the labeled amount of 
the therapeutic ingredient. The weight of the tablet being compressed is checked routinely so 
as to assure that tablet contains desired amount of the drug. For the tablets that contain more 
than 90% of the drug then weight variation test can be used as drug content uniformity of the 
tablet. Specified number of tablets is taken at random manner and average weight was 
determined. The average weight of tablets should not deviate from the maximum percentage 
deviation allowed. 
 Content uniformity: 
  It is the intended amount of drug substance contained by every tablet with little 
variation among tablets within a batch. A fundamental quality attribute for all pharmaceutical 
preparation is the requirement for a constant dose of drug between individual tablets. 
Specified numbers of tablets are individually assayed for their content and requirements for 
content uniformity are met if the amount of active ingredient in each dosage unit lies within 
the range specified in the monograph.  
 Disintegration:  
The disintegration test is a measure only of the time required under a given set of 
conditions for a group of tablets to disintegrate into particles. This test is useful as a quality – 
assurance tool for conventional (non sustained- release) dosage forms. Specified number of 
tablets was placed in the disintegration apparatus and the process is continued until the tablets 
get disintegrated.  
 Dissolution:   
Since drug absorption and physiological availability depend on having the drug substance in 
the dissolved state, suitable dissolution characteristics is important property of a satisfactory 
tablet. The dissolution test for measuring the amount of time require for a given percentage of 
the drug substance in the tablet to go into the solution under a specified set of condition is an 
in-vitro test. Specified numbers of tablets were taken in a dissolution apparatus containing 
suitable medium and the test is performed as per the specifications. 
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2. AIM AND OBJECTIVE  
The aim of the present study is to formulate and evaluate Film coated tablets of 
Fexofenadine Hydrochloride for the effective treatment of “Seasonal allergic rhinitis” and for 
treatment of “Chronic urticaria”. 
The main objective of this study was: 
• To perform the preformulation studies. 
• To formulate Fexofenadine Hydrochloride immediate release tablets. 
• To select the best formulation based on in-vitro studies for film coating. 
• To perform stability studies on the most satisfactory formulation. 
• To correlate with innovator product. 
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3. PLAN OF WORK 
The present work was carried out to formulate film coated Fexofenadine 
Hydrochloride tablets and to evaluate the in-vitro dissolution and stability studies for the 
prepared film coated Fexofenadine Hydrochloride tablets. It was planned to carry out this 
work as outlined below. 
 Literature review. 
 Drug profile. 
 Excipients profile. 
 Evaluation of API. 
 To perform drug and excipients compatibility studies.  
 Evaluation for the pre-compression parameters. 
 To formulate uncoated Fexofenadine Hydrochloride tablet by wet granulation method. 
 To evaluate the formulated uncoated Fexofenadine Hydrochloride tablets for the           
Following parameters. 
      a)  Tablet thickness. 
b)  Weight variation. 
c)  Tablet friability. 
d)  Content uniformity. 
e)  Tablet hardness. 
f)  Disintegration. 
g)  Dissolution 
 To coat the compressed tablet by film coating process using Hydroxypropyl                   
Methylcellulose (film polymer). Pan coating method was going to be used. 
 To evaluate the prepared film coated Fexofenadine Hydrochloride tablets. 
 To carry out the comparative in-vitro dissolution studies of prepared film coated 
Fexofenadine Hydrochloride tablet with the innovator product. 
 Stability studies on selected batch. 
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4. REVIEW OF LITERATURE 
 Nagendra Kumar D et al.,13 formulated fast dissolving tablets of fexofenadine 
hydrochloride to enhance patient compliance by sublimation method. In this method, 
camphor was used as the subliming agent (upto 30% w/w), crospovidone and 
croscarmellose sodium (2-8% w/w) as super disintegrants. The formulation, containing 
8% w/w of crospovidone and 30% w/w camphor as the subliming agent emerged as the 
overall best formulation (t50%4.3 min) based on drug release characteristics in pH 6.8 
phosphate buffer compared to commercial conventional tablet formulation (t50%15 
min).  
 Farya Zafar et al., 14 formulated and evaluated Fexofenadine 120mg tablets using low 
– cost directly compressible excipients. Three different formulations (F1-F3) were 
prepared by direct compression method using Avicel pH 101 in the range of 35-38%, 
Magnesium Stearate was used in the ratio of 2-3% and Crospovidone was used from 7-
9% in F1-F3. Among three formulations, F3 showed comparatively better results 
against different parameters as compared to F1 and F2. F3 showed 103.12% drug 
release, required 13 sec for disintegration and 100.18% assay and weight variation of 
224.77+1.49. Results indicated that direct compression is capable to manufacture 
tablets with excellent physical properties and showed adequate disintegration and 
dissolution.   
 Ana R et al.,15 developed and validated the dissolution tests for Fexofenadine 
hydrochloride capsules and coated tablets using an HPLC method. The appropriate 
conditions were determined after testing sink conditions, dissolution medium, and 
agitation intensity. The apparatus, paddle and basket, were applied to tablets and 
capsules, respectively. Fexofenadine hydrochloride capsules, products A and B, and 
coated tablets, products A, B and C were evaluated. The best dissolution conditions 
tested, for the products in each respective pharmaceutical dosage form were applied to 
evaluate the dissolution profiles. The parameters of difference factor, similar factor, and 
dissolution efficacy were employed.  
 Shah arpitkumar p. et al.,16 formulated tasteless complexes of Fexofenadine 
Hydrochloride with Kyron-134 and to formulate tasteless complex into fast-Dispersible 
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tablets (FDT).Tasteless Drug resin complexes (DRC) were prepared using combination 
of Kyron-134 & drug in different ratio (1:3) and evaluated for different factor affecting 
Drug-Resin Complexation, Complexation time, stirring time, soaking time, 
temperature, and effect of pH on Fexofenadine Hydrochloride loading on Kyron-134. 
Fexofenadine Hydrochloride release from FDT is obtained at salivary and gastric pH. 
Drug release from FDT in salivary pH was insufficient to impart bitter taste. Complete 
drug release was observed at gastric pH.  
 Hongxia Lin et al.,17 the effect of various surfactants (sodium cholate, sodium 
taurocholate, Tween 80 and Poloxamer F68) on enhancing the transepithelial 
permeabilityof Fexofenadine HCl was evaluated in a human nasal epithelial cell 
monolayer model. A dose-dependent reduction of cell viability was observed at higher 
than critical micelle concentration (CMC) of the surfactants, and the IC50 of non-ionic 
surfactants (Tween 80 and Poloxamer F68) was higher than that of ionic surfactants 
(sodium cholate and sodium taurocholate). These results imply that ionic surfactants are 
potentially useful permeation enhancers for nasal delivery of hydrophilic compounds, 
such as Fexofenadine HCl.  
 kuldeep yogendra desale, P D et al.,18  fast dissolving tablets of fexofenadine HCl 
were designed with a view to enhance patient compliance by direct compression 
method. The present work studied the effect of superdisintegrants on release rate of 
fexofenadine HCl in the form of fast disintegrating tablet. The superdisintegrants used 
were crosscarmellose sodium, crosspovidone and kyron T-314. The blends were 
prepared by direct compression technique. The tablets were evaluated for hardness, 
thickness, friability, drug content, weight variation and in-vitro drug release studies in 
pH 6.8. 
 Pradeep kumar T. at al.,19 developed the pharmaceutically equivalent, stable, cost 
effective and quality improved formulation of film coated Ticlopidine Hydrochloride 
tablets by direct compression technique. The three super disintegrant used in the study 
were croscarmellose sodium, microcrystalline cellulose and pregelatinised starch. The 
formulation containing combination of croscarmellose sodium, microcrystalline 
cellulose and Pregelatinised starch (6, 44.73, 54,75mg) showed minimum disintegration 
time and maximum drug release. 
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 Nasiruddin Ahmad farooqui et al.,20 formulated film coated tablets of Secnidazole by 
wet granulation method and the granules were compressed for tablets and they were 
coated with polymer for getting film coated tablets at specified conditions and the 
evaluation of film coated tablets were evaluated for various parameters as description, 
average weight, weight variation, hardness test, thickness, dissolution, related 
substances disintegration time and assay of tablet for compliance with acceptance 
criteria for formulation of Secnidazole film coated tablets.  
 Damodrharan .N et al.,21 developed small intestine targeting tablets of Doxycycline 
Hydrochloride by wet granulation method and enteric coated tablets. Six batches (F1-
F6) were formulated and evaluated for hardness, friability, weight variation, drug 
release, disintegration time and drug content. Among the six formulation F4 was 
showing 94% drug release and considered to be best formulation. 
 D. Srinivas, suhal Debnath et al., 22 formulated film coated tablet of Valsartan by 
direct compression, slugging and wet granulation techniques  exhibited the good 
powder flow than direct compression technique. Based on this investigation results, the 
drug release  from tablets increase with increasing concentration of super disintegrant.  
 R. Natarajan  Paroxetine et al.,23   formulated various formulations of immediate 
release tablet of Paroxetine using different superdisintegrants (Sodium Starch 
Glycolate, Croscarmellose, Crospovidone) and different grades of dicalcium phosphate 
by wet granulation method. The in vitro dissolution studies show the release is in the 
following order of superdisintegrants: Sodium Starch Glycolate > Croscarmellose > 
Crospovidone. These results suggest that, as determined by f2 factor (similarity factor) 
and maximum in vitro dissolution was found to be with Formulation F-7 and it clearly 
shows due to Sodium Starch Glycolate (4%). 
 Y. Dastagiri Reddy et al.,24 formulated  Gemfibrozil as Immediate release tablets 
using micro crystalline cellulose, pregelatinized starch, sodium starch glycollate and 
calcium stearate as excipient. It was compared with the innovator and effect of LOD on 
Gemfibrozil immediate release tablets were studied and to evaluated and the best 
formulations were coated with opadry white and comparative invitro dissolution profile 
of the coated formulation with that of the innovator product had shown that F6 
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formulation best matched with innovator and the formulations are loaded for the 
stability studies. 
 Jampani N et al.,25 Formulated immediate release tablets of Candesartan Cliexetil, 
prodrug of Candesartan by changing the concentration of ingredients. The immediate 
release tablets were prepared by wet granulation method to provide rapid onset of 
action. The main ingredients used in the formulations were lactose monohydrate, PEG, 
calcium CMC and MCC. The formulation containing 38% of MCC was selected as the 
optimized product because of the best results obtained from various test.  
 Galge Deepak et al.,26 Formulated immediate release tablets of Irbesartan by wet 
granulation method. Effect of various fillers and disintegrants were also explored. 
MCC, Colloidal silicone dioxide, croscarmellose sodium were used in the method. 
Final selection of the optimized batch was done based on pharmaceutical equivalence 
of development formulation to that of marketed one. 
 Shridhar J Pandya et al.,27 formulated Fexofenadine hydrochloride complex with 
inclusion complex with β-Cyclodextrin, because Fexofenadine hydrochloride having a 
poorly solubility and bioavailability. Inclusion complex with β-Cyclodextrin improve 
the characteristic and dissolution rate as compare to marketed product. Fexofenadine 
hydrochloride is an antihistaminic agent used for treatment of relieving hay fever and 
allergy symptoms, such as sneezing and red, itchy, tearing eyes. Its poor solubility is 
major problem for the patient compliance. Within 30 min, more than 90 % drug was 
released from the complexes, were good as compare to marketed product which shown 
in release profile. 
 Chowhan et al.,28  studied the comparative evaluations of aqueous film coated tablet 
formulations by high humidity aging. Compressed tablets of ticlopidine hydrochloride 
were coated with three aqueous film coating formulations and aged under 95% relative 
humidity at 23° and 37°. The in vitro dissolution of the drug from tablets coated with 
the formulation containing polymethacrylic acid esters before aging was slower than 
the tablets coated with the formulations containing hydroxypropyl methylcellulose or 
ethylcellulose dispersion. On aging, the in vitro drug dissolution of the coated and 
uncoated tablets decreased and the decrease depended on the film forming excipient in 
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the coating formulation and the temperature of aging. The tablets coated with the 
formulation containing polymethacrylic acid esters dissolved very slowly after aging. 
  Ruotsalainen et al.,29 studied aqueous film coating of tablets performed in a side – 
vented pan coater. The effects of film coating conditions and storage, surface 
morphology, moisture content and stability of hydroxyl propyl methyl cellulose coated 
tablets containing a moisture labile drug ASA were investigated. In addition, the time 
dependent dimensional changes of film coated tablets and the relevance of these 
changes to film adhesion were measured. The surface roughness was measured using a 
non contacting laser profilometer an optical roughness analyzer and a confocal laser 
scanning microscope. Process automation with an air flow rate measurement system, 
data storage and monitoring capability was used to control and analyse the film coating 
process. 
 Bytul M. Rahman et al.,30 prepared and evaluated the ketorolac tromethamine tablets 
with higher dissolution rates and compare them with marketed product. Direct 
compression method was adopted for preparation of tablet using different excipients 
namely; microcrystalline cellulose, spray dried lactose and starch 1500. The effect of 
excipients on the drug release from prepared tablets was also studied. All the tablet 
quality control tests were studied. All formulations showed good mechanical properties 
and complied with the USP 28 pharmacopeial standard requirements for uniformity of 
dosage units and friability. Formula No. 2 containing starch 1500 and microcrystalline 
cellulose gave higher percentage of ketorolac tromethamine release in comparison with 
other formulations and marketed product. 
 Tejash Serasiya*1 et.al,31 dispersible tablets of pheniramine maleate were prepared by 
direct compression method using various super disintegrants like Crospovidone, 
croscarmellose sodium, sodium starch glycolate, low substituted hydroxypropyl 
cellulose, pregelatinized starch. The tablets were disintegrating in–vitro within 20 to 51 
sec. Dissolution studies revealed that formulations containing 10% Crospovidone and 
formulation containing 10% croscarmellose sodium showed 100% of drug release, at 
the end of six min. The concentration of super disintegrants had an effect on 
disintegration time and in-vitro drug dissolution whereas hardness and friability of 
resulting tablets were found to be independent of disintegrant concentration. The two 
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formulations, one containing 10% of Crospovidone and second containing 10% 
croscarmellose sodium were found to give the best results. 
 Abdel Naser Zaid et al.,32 to developed and evaluated the stability of film coated 
Atorvastatin Calcium (AtC) tablets using Opadry-OY-B-28920. AtC uncoated tablets 
were developed and manufactured through the Wet Granulation process. Opadry-OY-
B-28920 white aqueous coating dispersion was used as film coating material. That 
aqueous film coating with Opadry-OY-B-28920 system is an easy and economical 
approach for preparing stable film coated AtC tablet of immediate release. 
  Heena Chaudhary et al.,33 formulated Fexofenadine hydrochloride is almost 
completely   absorbed from the gastro-intestinal tract following oral administration, but 
bioavailability is reported to be only about 45% due to hepatic first-pass metabolise, to 
prepared Transdermal patch of Fexofenadine hydrochloride. Preparation of transdermal 
patches of Fexofenadine hydrochloride using polymers: Hydroxypropyl methyl 
cellulose, Ethyl cellulose plasticized with Glycerol. The patches were evaluated for 
various parameters like Thickness, Water-Vapor Permeability, Tensile Strength, Drug 
Content, Diffusion and Dissolution studies. Prepared patches exhibited Zero Order 
Kinetics and the permeation profile was matrix diffusion type. In-vitro release study of 
Fexofenadine hydrochloride transdermal patch shown release of drug 79 % at 24 h and 
also follows zero order kinetics release. 
 Piao HM et al.,34 to enhance the solubility and bioavailability of poorly absorbable 
Fexofenadine, micro emulsion system composed of oil, surfactant and co-surfactant 
was developed for intranasal delivery. An increase in the micro emulsion region in 
pseudo-ternary phase systems was observed with increased surfactant concentration. 
The optimized micro emulsion formulations showed higher solubulization of 
Fexofenadine, i.e., F1 (22.64 mg/ml) and F2 (22.98 mg/ml), compared to its intrinsic 
water solubility (1.51 mg/ml). tmax was observed within 5 min after intranasal 
administration at 1.0 mg/kg dose, and the absolute bioavailability (0-4 h) was about 
68% compared to the intravenous administration in rats. Our results suggested that 
these micro emulsion formulations could be used as an effective intranasal dosage form 
for the rapid-onset delivery of Fexofenadine. 
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5. DRUG PROFILE 
35 
 FEXOFENADINE HYDROCHLORIDE 
DRUG   : Fexofenadine Hydrochloride. 
Structural Formula: 
                          
Molecular Formul :C32H39NO4.HCL. 
Chemical Name : (±)-4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-iperidinyl]-butyl]- 
  α, α- dimethyl benzene acetic acid hydrochloride. 
Molecular Weight : 538.13 
Category  : Histamine H1-receptor antagonist. 
Dose   : 30mg, 60mg, 180mg.  
Description  : Fexofenadine hydrochloride is a white to off-white crystalline powder.  
Solubility  : Freely soluble in methanol and ethanol, slightly soluble in chloroform 
  and water, and insoluble in hexane.Melting Point Range: 142.6
0
C  
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MECHANISM OF ACTION:
 36 
Fexofenadine hydrochloride, the major active metabolite of Terfenadine, is an 
antihistamine with selective peripheral H1-receptor antagonist activity. Both enantiomers of 
Fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects. 
Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea 
pigs and histamine release from peritoneal mast cells in rats. The clinical significance of 
these findings is unknown. In laboratory animals, no anti cholinergic or alpha1-adrenergic 
blocking effects were observed. Moreover, no sedative or other central nervous system 
effects were observed. Radiolabeled tissue distribution studies in rats indicated that 
Fexofenadine does not cross the blood-brain barrier.  
PHARMACOKINETICS: 
Absorption: 
Fexofenadine hydrochloride is rapidly absorbed after oral administration with peak plasma 
concentrations being reached in 2 to 3 hours. 
Distribution: 
Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and 
α1-acid glycoprotein.  
Metabolism: 
About 5% of the total dose is metabolized, mostly by the intestinal mucosa, with only 0.5 to 
1.5% of the dose undergoing hepatic biotransformation. 
Elimination: 
Elimination half-life of about 14 hours has been reported although these may be prolonged in 
patients with renal impairment. Excretion is mainly in the faeces with only 10% being present 
in the urine. Fexofenadine hydrochloride dose not cross the blood brain barrier. 
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ADVERSE REACTIONS:
37 
The most common adverse reactions were headache, back pain, dizziness, stomach 
discomfort, drowsiness, fatigue, nausea, dyspepsia and dysmenorrhoea.   
PRECAUTIONS: 
Patients with decreased renal function should be given a lower initial dose (one tablet per 
day) because they have reduced elimination of Fexofenadine.  
INDICATIONS: 
Seasonal Allergic Rhinitis 
Fexofenadine hydrochloride tablets are indicated for the relief of symptoms associated 
with seasonal allergic rhinitis in adults and children’s of 6 years age and older. 
Chronic Idiopathic Urticaria 
Fexofenadine hydrochloride tablets are indicated for treatment of uncomplicated skin 
manifestations of chronic idiopathic urticaria in adults and children’s of 6 years age and 
older. 
CONTRAINDICATIONS: 
Fexofenadine hydrochloride tablets are contraindicated in patients with known 
hypersensitivity to Fexofenadine and any of the ingredients of Fexofenadine hydrochloride. 
Rare cases of hypersensitivity reactions with manifestations such as Angioedema, chest 
tightness, dyspnea, fushing and systemic anaphylaxis have been reported. 
DOSAGE AND ADMINISTRATION:
38 
Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria:  
Adults and Children’s of 12 Years and Older: The recommended dose of 
Fexofenadine hydrochloride tablets is 60 mg twice daily or 180 mg once daily. A dose of 60 
mg once daily is recommended as the starting dose in patients with decreased renal function.  
Children’s of 6 to 11 Years: The recommended dose of Fexofenadine hydrochloride tablets is 
30 mg twice daily. A dose of 30 mg once daily is recommended as the starting dose in 
pediatric patients with decreased renal function. 
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6. EXCIPIENTS PROFILE (6.1- 6.12)
40 
6.1. MICROCRYSTALLINE CELLULOSE 
 Structural formula                                    
 
 Non proprietary name         
 BP  :   Microcrystalline cellulose 
 JP  :   Microcrystalline cellulose 
PhEur  :   Cellulosum microcrystallinum 
USPNF :  Microcrystalline cellulose 
Empirical formula  
  (C6H10O5) n 
 Molecular weight  
   ≈36000  where n≈220. 
Synonym 
Avicel, Cellulose gel, Tabulose Crystalline cellulose, E460, Emcocel, Fibrocel, 
Vivacel 
Chemical name  
  Cellulose 
Functional category  
Adsorbent, suspending agent, tablet disintegrant, capsule and tablet diluents. 
 Physical state    
It is purified, partially depolymerised Cellulose that occurs white, odourless, tasteless, 
crystalline powder composed of Porous particles. 
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 Typical properties                                    
 Density (bulk)    - 0.337 g/cm
3
 
 Density (tapped) - 0.478 g/cm
3
 
 Density (true)      -1.512-1.668 g/cm
3
 
 Melting point     - Characteristics at 260-270
o
C 
Table No: 1 Properties of some commercially available grades of microcrystalline cellulose 
Grade 
Nominal 
mean 
particle 
size(µm) 
Particle size analysis 
Moisture content (%) 
Mesh size 
Amount 
retained (%) 
Avicel PH-
101 
50 
60 
200 
≤1.0 
≤30.0 
≤5.0 
Avicel PH-
102 
100 
60 
200 
≤8.0 
≥45.0 
≤5.0 
Avicel PH-
103 
50 
60 
200 
≤1.0 
≤30.0 
≤3.0 
Avicel PH-
105 
20 400 ≤1.0 ≤5.0 
Avicel PH-
112 
100 60 ≤8.0 ≤1.5 
Avicel PH-
113 
50 
60 
200 
≤1.0 
≤30.0 
≤1.5 
Avicel PH-
200 
180 
60 
100 
≥10.0 
≥50.0 
≤5.0 
Avicel PH-
301 
50 
60 
200 
≤1.0 
≤30.0 
≤5.0 
Avicel PH-
302 
100 
60 
200 
≤8.0 
≥45.0 
≤5.0 
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 Solubility  
Slightly soluble in 5% w/v Sodium Hydroxide solution, Practically insoluble in water, 
acids, and most Organic solvents.  
Stability & Storage condition  
Microcrystalline cellulose is a stable though hygroscopic material. The bulk material 
should be stored in a well closed container in a cool and dry place. 
Incompatibilities   
Incompatible with strong oxidizing agents. 
Applications 
It is widely used in pharmaceuticals, primarily as binder/ diluents in oral tablet and 
capsule formulations. Where it is used in both wet granulation and direct compression 
processes. MCC also has some lubricant   and disintegrant properties that make it useful in 
tableting.   
6.2. PREGELATINISED STARCH 
 Structural formula          
 
Non proprietary name     
USP       :      Pregelatinised starch. 
PhEur       :      Starch, Pregelatinised. 
 Synonym          
Compressible starch, instant starch, starch1500, prejel. 
Chemical name         
Pre-gelatinised starch. 
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Empirical formula           
 (C6H10O5)n 
Molecular weight            
 300-100g/mol. 
Functional category              
Tablet and capsule binder, diluent, disintegrant. 
Physical state 
Moderately coarse to fine, white to off-white coloured powder. It is odorless and has a 
slight characteristic taste. 
Typical properties             
Density (Bulk)                   :       0.586 g/cm
3
 
Density (tapped)                :       0.879 g/cm
3
 
Density (true)         :       1.156 g/cm
3 
Solubility         
Slightly soluble in cold water.  
Insoluble in organic solvents. 
Stability & Storage condition  
It is a stable though hygroscopic material, which should be stored in a   well- closed 
container in a cool and dry place. 
Applications    
Pregelatinised starch is a modified starch used in tablet formulations as a binder, 
diluents, and disintegrant. It may be used as a binder in wet  granulation and dry compression  
processes.    
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                          Table No: 2 Different concentration of Pregelatinised Starch 
Use Concentration (%) 
Tablet binder (wet granulation) 5–75 
Tablet disintegrant 5–20 
Diluent (hard gelatin capsules) 5–10 
Tablet binder (direct compression) 5–10 
6.3 CROSCARMELLOSE SODIUM 
Structural formula  
 
Non proprietary name  
BP  :  Croscarmellose sodium 
JPE  :  Croscarmellose sodium 
USP  :  Croscarmellose sodium 
Molecular weight     
 90,000-7,00,000. 
Synonym      
Ac-Di-Sol, Solutab, Primellose, Pharmacel Xl 
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Chemical name     
Cellulose, Carboxy methyl ether, 
Physical state      
Croscarmellose sodium occurs as an odourless, white coloured powder. 
Functional category  
 Tablet and capsule disintegrant 
Typical properties       
       Density (bulk)             :  0.529 g/cm
3
 
       Density (tapped)             :  0.819 g/cm
3
 
       Density (true)             : 1.543 g/cm
3 
Solubility                
Insoluble in water rapidly swells to 4-8 times of its original volume on contact with 
water. 
Stability & Storage Condition      
Croscarmellose sodium is a stable though hygroscopic material. It should be stored in 
a well-closed container in a cool, dry place. 
Incompatibilities               
The efficacy of Croscarmellose sodium may be slightly reduced in tablet formulations 
prepared by either wet granulation or direct compression process which contains hygroscopic 
excipients such as Sorbitol. 
Applications  
 Croscarmellose sodium is used in oral pharmaceutical formulations as a disintegrant 
for tablet, capsule and granules. In tablet formulations, croscarmellose sodium may be used in 
both direct compression and wet granulation processes. 
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 Table No: 3 Different concentration of Croscarmellose sodium  
Use Concentration (%) 
Disintegrant in capsules 10-25% 
Disintegrant  in tablets 0.5-5.0% 
6.4. LACTOSE MONOHYDRATE 
 Nonproprietary Names  
 BP          :         Lactose monohydrate 
 USPNF   :        Lactose monohydrate 
Chemical Name       : O-β-D-Galactopyranosyl-(1-4)-α-D-glucopyranose monohydrate     
Emprical Formula            
           C12H22O11.H2o 
Molecular Weight   
           360.31  
Functional category       
Binding agent; diluents for dry-powder inhalers; tablet binder, tablet and capsule 
diluents 
Physical state         
 Lactose occurs as white to off-white crystalline particles or powder. Lactose is 
odorless and slightly sweet-tasting; α- lactose is approximately 20 % as sweet as sucrose, 
while β-lactose is 40% as sweet. 
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Typical Properties          
 Angle of repose: 33
o
 for Pharmatose DCL 15; 32
o
 for Tablettose 70 and Tablettose 80  
Density (true)      :   1.545 g/cm
3
 (α-lactose monohydrate) 
Melting point      :   201-202
o
C (for dehydrated α-lactose monohydrate) 
Moisture content  
Lactose monohydrate contains approximately 5% w/v water of Crystallization and 
normally has a range of 4.5-5.5% w/v water content. 
Solubility            
Table No: 4 Solubility of lactose monohydrate in different solvents  
Solvent Solubility at 20
o
c unless otherwise stated 
Chloroform Practically insoluble 
Ethanol Practically insoluble 
Ether Practically insoluble 
Stability & Storage conditions  
 Lactose should be store in a well closed container in a cool dry place. 
Applications   
Lactose is widely used in tablets and capsules as filler, and to a more limited extent in 
lyophilized products and infant formulas. It is used in dry-powder inhalation as diluents. 
Usually, in the preparation of tablets by wet-granulation method or milling, fine grades of 
lactose are used. Lactose is also used to prepare sugar-coating solutions in combination with 
sucrose. 
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 6.5. STARCH 
 Nonproprietary Names: 
 BP                      :   Maize starch, Potato starch, Rice starch, Tapioca starch, Wheat starch. 
 JP                       :  Corn starch, Potato starch, Rice starch, Wheat starch. 
 PhEur     :  Maydis amylum (maize starch), Solani amylum (potatostarch),Oryzae        
amylum (rice starch), Tritici amylum (wheat starch). 
USPNF               :  Corn starch, Potato starch, Tapioca,Wheat starch. 
Synonyms                        
 Amido; amidon; amilo; amylum; Aytex P; C*PharmGel, Fluftex W; Instant  Pure-
Cote; Melojel; Meritena; Paygel 55; Perfectamyl D6PH; Pure-Bind; Pure-Cote; Pure-Dent; 
Pure-Gel; Pure-Set; Purity 21; Purity 826; Tablet White. 
Chemical Name             
Starch  
Empirical Formula       
(C6H10 O5)  n. 
Molecular Weight         
50 000–160 000. 
Functional Category     
Glidant, tablet and capsule diluent; tablet and capsule disintegrant; tablet binder. 
Physical state               
 Starch occurs as an odorless and tasteless, fine, white-colored powder comprising     
very small spherical or ovoid granules. 
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Typical Properties      
 Acidity/alkalinity   :  pH = 5.5–6.5 
 Density (bulk)           : 0.462 g/cm3  
 Density (tapped)       : 0.658 g/cm3 
 Density (true)            : 1.478 g/cm3 
 Solubility                      
Practically insoluble in cold ethanol (95%) and in cold water. 
Stability & Storage Conditions    
Dry, unheated starch is stable if protected from high humidity. When used as a diluent 
or disintegrant in solid-dosage forms; starch is considered to be inert under normal storage 
conditions. Starch should be stored in an airtight container in a cool, dry place. 
 Applications                
Starch is used as excipients primarily in oral solid-dosage formulations where it is 
utilized as a binder, diluents, and disintegrant. In tablet formulations, freshly prepared starch 
paste is used at a concentration of 5–25% w/w in tablet granulations as a binder. Starch is one 
of the most commonly used tablets disintegrant at a concentration of 3–15% w/w. 
Solubility                         
  Freely soluble in acids, chloroform, ethanol, ketones, methanol and  water. 
Incompatibilities  
Thiomerosal adversely affected by the formation of complexes with povidone. 
Applications 
Primarily used in solid dosage form in tablet povidone solution used as binder in wet 
granulation processes. It is used as solubilizer in oral and parenteral formulation and has been 
shown to enhanced dissolution of poorly soluble drug from solid dosage form. It is also used 
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as coating agent. Also used as suspending, stabilizing, or viscosity increasing agent in a 
number of topical and oral suspension and solution. 
6.7. COLLOIDAL SILICON DIOXIDE 
Structural formula  :  SiO2 
Non proprietary name          
BP              :  Colloidal anhydrous silica 
PhEur   :  Silica colloidal is anhydrica 
USP   :  Colloidal silicon dioxide 
Synonym               
  Aerosil, fumed silica, Cab-o-sil, Colloidal silica, Silica anhydride, Silicon dioxide 
fumed, wacker HDK. 
Chemical name                 
Silica 
Molecular weight 60.08 
Functional category      
Adsorbent, Anticaking agent, Glidant, Suspending agent, Tablet disintegrant, 
Viscosity increasing  agent.        
Physical state         
 It is a light, loose, bluish-white coloured, odorless, tasteless,  nongritty, amorphous 
powder. 
Typical properties  
Density (bulk)  :        0.029-0.042 g/cm
3
 
 pH              :        3.5-4.4 (4% w/v aqueous dispersion) 
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Stability & Storage condition  
It is hygroscopic, but absorbs large quantities of water without liquefying. It should be 
stored in a well-closed container. 
Incompatibilities      
 Incompatible with diethyl stilbesterol preparations. 
Application              
It is widely used in pharmaceutical formulations to improve the flow properties of dry 
powders. It is used as glidant in 0.1-0.5%. 
Table No: 5 Different concentration of Colloidal silicon dioxide 
Use Concentration in % 
Aerosols 0.5-2.0 
Emulsion Stabilizer 1.0-5.0 
Glidant 0.1-0.5 
Suspending and Thickening agent 2.0-10.0 
6.2.8. MAGNESIUM STEARATE 
Structural formula  :        [CH3 (CH2)16COO]2 Mg 
Empirical formula  :       C36H70MgO4 
Molecular weight  :       591.34 
Chemical name  :       Octadecanoic acid, Magnesium salt 
Non proprietary name          
BP               :       Magnesium stearate 
JP    :       Magnesium stearate 
PhEur    :       Magnesii stearas 
USP    :       Magnesium stearate 
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Synonym    
Magnesii stearas, Magnesium octadeconate, Magnesium salt. 
Physical state   
It is a fine, white, precipitated or milled, impalpable powder of low bulk density, 
having a faint odour of stearic acid and a characteristic taste. 
Functional category  
 Tablet and capsule lubricant. 
Typical properties                  
        Density (bulk)  :       0.159 g/cm
3
 
        Density (tapped)  :       0.286 g/cm
3
 
        Density (true)  :       1.092 g/cm
3
 
        Melting point  :       117-150
o
c 
Solubility 
 Practically insoluble in ethanol, ether, and water 
 Slightly soluble in warm benzene and ethanol. 
Stability & Storage condition 
  Magnesium stearate is stable and should be stored in a well closed container  in a cool 
dry place. 
Incompatibilities                      
It is incompatible with strong acids, alkalies, and iron salts. It cannot be used in 
products containing aspirin, vitamins and alkaloidal salts. 
Applications        
It is widely used in cosmetics, food products and pharmaceutical formulations. It is 
used as a lubricant in capsule and tablet manufacture at concentration between 0.25-5.0 %. 
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6.9. HYPROMELLOSE 
Structural formula   
 
Where, R is H, CH3, or CH3 CH(OH)CH2 
Molecular weight       :     80,000-140,000. 
Chemical name          :     Cellulose-2-hydroxypropyl methyl ether. 
Non proprietary name            
BP                :      Hypromellose 
JP                :      Hydroxypropyl methylcellulose. 
USP                :      Hypromellose. 
Synonym                                   
Methocel, Metolose, Benecel MHPC, Pharmacoat.            
Physical state                                    
White to off-white powder or flakes. 
Melting point                                 
Softens at 1308C; chars at 260–2758C. 
pH
                                                                 
5.5 – 8.0 for a 1% w/w aqueous solution. 
Solubility                                       
It is soluble in cold water but insoluble in chloroform, ethanol (95%), and ether, but 
soluble in mixture of ethanol and dichloro -methane, mixture of methanol and dichloro -
methane, mixture of water and alcohol.                                                                                
  
EXCIPIENTS PROFILE 
 
 Page 51 
 
Viscosity                                        
  A wide range of viscosity grades are commercially available.  
              Table No: 6 Different Grades of Hypromellose with its Viscosity 
Methocel Grade Viscosity (m Pa) 
K100LV 80-120 
K4M 3000-5600 
K15M 12000-21000 
E4M 3500-5600 
E3PREM.LV 2.4-3.6 
E5PREM.LV 4-6 
E50PREM.LV 40-60 
E6PREM.LV 5-7 
E15PREM.LV 12-18 
                                                                             
Stability & Storage condition      
It is a stable material although it is hygroscopic after drying. Ii shoud be stored in a 
well- closed container, in a cool and dry place. 
Applications                                        
It is used as a viscosity control agent, gelling agent, film former, stabilizer, dispersant, 
lubricant, binder emulsifying agent, and include suspending agent. End applications 
adhesives and glues, agriculture, building materials, personal care products, detergents and 
surfactants, paints, printing inks and coatings, pharmaceutical products, polymerization and 
textiles. 
Incompatibility                                   
Incompatible with some oxidizing agents.  
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6.10. POLY ETHYLENE GLYCOL- 400 
Chemical Name       :  α-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl) 
Empirical Formula   :  HOCH2 (CH2OCH2) mCH2OH  
                          Where, m represents the average number of oxyethylene groups. 
Molecular Weight :  76.09 
Nonproprietary Names: 
BP  :  Macrogol 
JP  :  Macrogol 400 
Ph.Eur  :  Macrogola 
USPNF :  Polyethylene glycol 
Synonyms        
  Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; PluriolE, polyoxyethylene 
glycol. 
Melting point          
59
0
C. 
Functional Category 
Ointment base,  plasticizer; solvent, suppository base, tablet and capsule lubricant. 
Solubility                   
Soluble in water, acetone, alcohols, benzene, glycerin, and glycols. 
Description                
Occur as clear, colorless or slightly yellow-colored, viscous liquids. They have a 
slight but characteristic odor and a bitter, slightly burning taste. 
Density                      
  1.11–1.14 g/cm3 at 25ºC 
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Stability and Storage conditions  
Polyethylene glycols are chemically stable in air and in solution, although grades with 
a molecular weight less than 2000 are hygroscopic. Polyethylene glycols do not support 
microbial growth, and they do not become rancid. Polyethylene glycols should be stored in 
well-closed containers in a cool, dry place. Stainless steel, aluminum, glass, or lined steel 
containers are   preferred for the storage of liquid grades. 
Incompatibilities  
Incompatible with some coloring agents. 
Applications         
Plasticizer, tablet binder, suspending agent, emulsifying agent, suppository base, 
disintegrant. 
6.11. IRON OXIDE 
Empirical Formula: Fe3O4. 
Synonym                    
Ferric hydroxide;  Ferric hydrate; Ferric oxide hydrated. 
 Description              
  Iron oxides occur as yellow, red, black, or brown powder.  
Molecular Weight     
 231.54 
 Functional category   
  Colorants       
Solubility                     
    Soluble in strong mineral acids, practically insoluble in water. 
Melting point             
 1538
0
C. 
Density                      
5.1 g/cm
3
.  
 Stability & Storage    
  It should be stored in well-closed containers in a cool, and dry place. 
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Incompatibilities              
Iron oxides have been reported to make hard gelatin capsules, brittle at higher 
temperatures when the residual moisture is 11-12%. This factor affects the use of iron oxides 
for coloring hard gelatin capsules and will limit that can be incorporated into the gelatin 
material. 
Applications              
Iron oxides are widely used in cosmetics, foods, and pharmaceutical applications as 
colorants and UV absorbers. 
6.12. TITANIUM DIOXIDE   
Titanium Dioxide is a white, amorphous, odorless, and tasteless powder. Although the 
average particle size of titanium dioxide powder is less than 1 mm, commercial titanium 
dioxide generally occurs as aggregated particles of approximately 100 mm diameter. 
Synonym                    :  Anatase titanium dioxide; Brookite titanium dioxide. 
Empirical Formula   :  TiO2 
Molecular Weight     :  79.88 
Melting point             :  1855
0
C 
Density (bulk)            :  0.4–0.62 g/cm3. 
Density (tapped)        :  0.625–0.830 g/cm3. 
Density (true)            : 3.8–4.1 g/cm3. 
Applications              
Titanium dioxide is widely used in confectionery, cosmetics, foods, in the plastics 
industry, and in topical and oral pharmaceutical formulations as a white pigment in film-
coating suspensions, sugar-coated tablets, and gelatin capsules. Titanium dioxide may also be 
admixed with other pigments. Titanium dioxide is also used in dermatological preparations 
and cosmetics such as sunscreens. 
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7.  MATERIALS AND SUPPLIERS 
LIST OF MATERIALS 
Table No: 7 List of Materials and its suppliers 
S. No 
Materials Manufacturers/suppliers 
1 Fexofenadine hydrochloride Vasudha pharma chemical limited 
2 Microcrystalline cellulose Vijlak pharma, india 
3 Microcrystalline cellulose 102 Weiming phrmaceuticals, india 
4 Pregelatinised starch Colorcon asia pvt. Ltd 
5 Croscarmellose sodium Minglai chemicals co, ltd 
6 Lactose monohydrate DVM international. Ltd 
7 Starch Maize products 
8 Povidone Namberg india co.  
9 Colloidal silicon dioxide Cabot sanmar 
10 Magnesium stearate Vijlak pharma 
11 Hydroxyl propyl methyl cellulose_15Caps Samsing chemicals 
12 Hydroxyl propyl methyl cellulose_E5 Samsing chemicals 
13 Polyoxy ethylene glycol_400 Vasudha chemicals pvt ltd 
14 Iron oxide red Neshiel chemical pvt limited 
15 Titanium dioxide BASF 
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LIST OF INSTRUMENTS 
Table no: 8 List of Instrument and  its suppliers 
S. No Intruments Manufacturers/suppliers 
1 Elecronic balance Adventurer Mettler Toleda 
2 pH Meter Lab India   
3 FTIR Spectrophotometer 8300 Perkin Elmer 
4 HPLC  Shimadzu-corporation, Japan 
5 Disintegration tester Electrolab,ED-21, India 
6 Dissolution test apparatus(Disso 2000) Lab India dissolution test apparatus 
7 Friability test apparatus Electro lab,ET-2, India 
8 Bulk density apparatus Thermonik, Campbel Electronics 
9 Melting point apparatus Lab India 
10 Moisture balance OHAVS moisture balance 
11 Vernier calipers Mitutoyo corps, Japan 
12 Hardness tester Monsanto test apparatus 
 
LIST OF EQUIPMENTS 
Table No: 9 List of equipments and its suppliers 
S. No Equipments Manufacturers/suppliers 
1 Humidity chamber  Thermolab India 
2 Fluidized bed dryer Alliance Engineering Company, Bombay 
3 8 Station tablet compression machine Accura, Ahmedabad 
4 Coating pan Air creation India 
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8. EXPERIMENTAL SECTION 
8.1 PREFORMULATION STUDY
41 
Preformulation studies are designed to determine the compatibility of initial 
excipients with the active substance for a biopharmaceutical, physicochemical and analytical 
investigation in support of promising experimental formulations. Successful formulations 
take into account a drug’s interactions with the physicochemical properties of other 
ingredients [and their interactions with each other] to produce a safe, stable, beneficial and 
marketable product. 
 The basic purpose of the preformulation activity is to provide a rational basis for the 
formulation approaches, to maximize the chances of success in formulating an acceptable 
product and to ultimately provide a basis for optimizing drug product quality and 
performance. The first step in any formulation activity is careful consideration of a complete 
physicochemical profile of the active ingredients available, prior to initiating a formulation 
development activity.  
CONTENT OF PREFORMULATION STUDIES: 
1. Solubility: 
1 part of drug was taken and dissolved in 5 ml of methanol, and found that the drug 
was freely soluble in methanol. 1 part of drug was taken and dissolved in 10 ml of chloroform 
or 10 ml of water, and found to be that the drug was slightly soluble in chloroform and water.  
2. Melting point:  
Required amount of drug was taken in capillary tube, and then the capillary tube was 
kept in melting point apparatus. The melting point was determined by using LAB INDIA 
melting point apparatus. 
3. Loss on drying (%): 
Loss on drying is an expression of moisture content. The loss on drying test is 
designed to determine the amount of water and volatile matters in a sample, when the sample 
is dried under specified conditions. The loss on drying of the blend (1g) was determined by 
using electronic LOD (OHAVS moisture balance) 
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DRUG EXCIPIENT COMPATIBILITY STUDIES:
42 
Drug-excipient compatibility studies are carried out for designing a chemically stable 
formulation for clinical and commercial development. Drug excipient compatibility studies 
are conducted during preformulation to select the most appropriate excipients, to study the 
compatibility of active ingredients with selected excipients and to prove that the selected 
excipients are compatible with the active ingredient. The active ingredients and the excipients 
were mixed in the selected ratios using a mortar and pestle. The mixtures are transferred into 
glass vials and sealed. The samples were kept at 40ºC±2ºC/75%±5% RH for 4 weeks. The 
samples were analyzed for physical and chemical incompatibilities. 
IR SPECTRAL STUDIES: 
43
  
KBr pellet technique was followed for this study. In this the sample and the KBr were 
taken in 1:300 ratio.The mixture of sample and KBr was triturated to make fine powder. The 
fine powder was made into pellets by using pellitizer. The transparent pellets were placed in 
the Perkin elmer FT-IR spectrometer and the spectrum was recorded. The FT-IR analysis was 
done for both Fexofenadine Hydrochloride and also for prepared formulations.The 
frequencies of the possible peaks of FT-IR spectra of Fexofenadine Hydrochloride should 
match with the drug - excipients spectra. 
Table No: 10 List of Excipients for Preformulation Study 
S.No. INGREDIENT USE 
DRUG-EXCIPIENTS 
RATIO 
1. Croscarmellose sodium Disintegrant 1:5 
2. Microcrystalline Cellulose Diluent 1:10 
3. Starch Binder/Diluent 1:10 
4. Povidone Binder 1:0.5 
5. Lactose Monohydrate Diluent 1:10 
6. Pregelatinized Starch Binder/Diluent 1:10 
7. Magnesium stearate Glidant 1:0.25 
8. Titanium dioxide Opacifier 1:1 
9. Colloidal silicon dioxide Lubricant 1:0.5 
10. Polyethylene glycol 400 Plasticizer 1:1 
11. Hypromellose E15 Binder/Diluent 1:1 
12. Microcrystalline Cellulose 102 Diluent/ Disintegrant 1:10 
13. Hypromellose E5 Binder/Diluent 1:1 
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8.2   FORMULATION DEVELOPMENT OF FEXOFENADINE HYDROCHLORIDE           
        180mg TABLETS   
Table No: 11 Formulation development of Fexofenadine Hydrochloride 180mg tablets 
S. No Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 
Fexofenadine 
Hydrochloride 
 
180 
 
180 
 
180 
 
180 
 
180 
 
180 
 
180 
 
180 
 
180 
2 Starch 132 124 _ _ _ _ _ _ _ 
3 Lactose monohydrate _ _ 180 _ _ _ _ _ _ 
4 
Microcrystalline 
cellulose 
Intra _ _ _ 78 121.5 121.5 220 120 120 
Extra 256 275 144 121.5 _ _ _ _ _ 
5 
Pregelatinsed 
starch 
Intra _ _ 72 180 180 180 30 120 120 
Extra _ _ _ _ _ 72.5 80 50 50 
6 
Croscarmellose 
sodium 
Intra 20 9 18 18 20 20 18 18 18 
Extra _ _ _ 18 20 20 18 18 18 
7 Povidone 6 6 _ _ _ _ 15 15 15 
8 
Microcrystalline 
cellulose 102 (Extra) 
_ _ _ _ 72.5 _ 30 70 70 
9 
Colloidal silicon 
dioxide 
_ _ 3 _ _ _ 3 3 3 
10 Magnesium stearate 6 6 3 4.5 6 6 6 6 6 
11 Purified water q. s q. s q. s q. s q. s q. s q. s q. s q. s 
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Formulation of the Tablet: 
The process involved in the tablet formulation by wet granulation method is represented in 
the schematic method.  
Steps involved in the formulation of Fexofenadine Hydrochloride Tablets by Wet 
Granulation Method: 
Weighing of ingredients 
↓ 
Sifting 
↓ 
Dry mixing 
          ↓ Binder 
Granulation & Drying 
                            ↓ Semi passing (16#) 
Milling (Granules passed through Sieve 20#) 
↓ 
Blend 
↓ 
Lubrication 
↓ 
Compression 
↓ 
Coating 
↓ 
Packing 
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8.3 EVALUATION OF GRANULES AND POWDER BLENDS:
44 
8.3.1. PRE-COMPRESSION PARAMETERS:   
The following parameters were determined for the granules (or) powders blends 
before compression into tablets. 
 BULK DENSITY: 
 
 
Bulk density is defined as powder mass divided by its bulk volume without any 
tapping. Powder bulk density depends primarily on particle size distribution, particle shape, 
and the tendency of particles to adhere to each other. Some particles may pack loosely, 
leading to fluffy and light powder, while others may contain smaller particles that site 
between larger particles to fill the void, leading to dense and heavy powder. Bulk density is 
often used to calculate the batch size for blender and granulator.
 
Weighed quantity of granules and powder blends from each formulation was taken in 
a measuring cylinder and the initial volume of the granules in the measuring cylinder was 
noted. Bulk density of the granules was calculated by using the following formula. 
Pb = M/V b 
Where, 
Pb = Bulk density M = Weight of sample in g, 
Vb = Final volume of powder blend in cm
3
. 
 TAPPED DENSITY:  
Tapped density of a powder is the ratio of the mass of the powder to the volume 
occupied by the powder after it has been tapped for a defined period of time. Tapped density 
was measured by introducing the known quantity of granules into a graduated cylinder and 
carefully leveling off the granules without compacting it. The cylinder was mechanically 
tapped by placing on the bulk density apparatus. The volume was measured by tapping the 
granules for 500 times. Then the tapping was done for 750 times and the tapped volume was 
noted. The tapped density was calculated by using the following formula:  
Pt = M/Vt 
Where, 
           Pt   = Tapped density, M = Weight of the sample in g, 
          Vt = Tapped volume of powder blend in cm
3 
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 COMPRESSIBILITY INDEX AND HAUSNER’S RATIO: 
The compressibility index is a measure of the propensity of a powder to consolidate. 
As such it is a measure of the relative importance of inter-particle interactions. In a free 
flowing powder, such interactions are generally less significant and the bulk and tapped 
densities will be closer in value. For poorer flowing material, there are frequently greater 
interparticle interactions; bridging between particles often results in lower bulk density and a 
greater difference between the bulk and tapped densities. These differences in particle 
interactions are reflected in the compressibility index.The compressibility index of the 
granules was determined by Carr compressibility index and the Hausner’s ratio was 
calculated by using the formula: 
Hausner’s Ratio     = Tapped density / Bulk density. 
Carr’s index (%)   = [(TD-BD) / TD] x100. 
 Where, 
TD = Tapped density, BD = bulk density. 
Table No:  12 Scale of flowability 
Flow Character Compressibility Index (%) Hausner’s Ratio 
Excellent < 10 1.00 – 1.11 
Good 11 – 15 1.12 – 1.18 
Fair 16 – 20 1.19 – 1.25 
Passable 21 – 25 1.26 – 1.34 
Poor 26 – 31 1.35 – 1.45 
Very Poor 32 -37 1.46 – 1.59 
Very, Very Poor > 38 > 1.60 
8.3.2. POST COMPRESSION PARAMETERS:
45 
The tablet was evaluated for its parameters like hardness, thickness, friability, weight 
variation, and assay and in-vitro release studies.  
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 APPEARANCE: 
The tablets should be free from cracks, depressions, pinholes etc. The surface of the 
tablets should be smooth. The tablets were examined externally under a biconvex lens for 
surface cracks, depressions and pinholes. 
THICKNESS: 
The thickness of a tablet can vary without any change in its weight. This is generally 
due to the difference of density of granules, pressure applied for compression and the speed 
of compression. The thickness of a tablet can be determined with the help of vernier caliper 
or screw guage. Five tablets from each batch were used, and average values were calculated. 
The thickness was denoted in millimeter. 
HARDNESS: 
Hardness or tablet crushing strength is the force required to break a tablet in a diametric 
compression, was measured using Monsanto tablet hardness tester. The values were 
expressed in Kg/cm
2
. The hardness was determined using the Monsanto hardness tester. The 
tablet was held along its oblong axis in between the two jaws of the tester, at this point 
reading should be zero kg/cm
2
. Then constant force was applied by rotating the knob until the 
tablet fractured. 
FRIABILITY: 
Specified number of tablets are weighed and placed in the tumbling chamber of the 
friabilator and rotated for four minutes at a speed of 25 Rpm.. During each revolution the 
tablets fall from a distance of six inches to undergo shock. After 100 revolutions the tablets 
are dusted and again weighed and the loss in weight indicates the friability.    
Finally can be determined by the following formula 
                                       F = W1 – W2 / W1 × 100 
Where, 
                    W1 = Weight of the tablets before test 
                     W2 = Weight of the tablets after test 
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WEIGHT VARIATION TEST: 
20 tablets were selected randomly from a batch and were individually weighed and 
then the average weight was calculated. The tablets meet the USP specifications if not more 
than two tablet are outside the percentage limit and if no tablet differs by more than two times 
the percentage limits.  
 %Deviation = Individual Weight – Average Weight / Average Weight × 100   
  Table no: 13 Weight variation tolerance for  tablets 
AVERAGE WEIGHT OF TABLETS AVERAGE WEIGHT OF TABLETS 
80mg or less ±10% 
More than 80mg and less than 250mg ±7.5% 
250mg or more ±5% 
DISINTEGRATION TEST:   
The in-vitro disintegration test was carried out at 37°±2°C in 900ml of distilled water. 
The in-vitro disintegration time of 6 tablets from each formulation were determined using 
disintegration test apparatus. One tablet was placed in each of the six tubes of the apparatus 
containing distilled water. One disk was added to each tube. The time taken in minutes for 
complete disintegration of the tablet with no mass remaining in the apparatus was noted.   
 ASSAY:
 
Chromatographic Condition: 
Column            : 4.6-mm×25 cm; 5-µm packing L11. 
Flow Rate        : 1.5 ml/min 
Column Temperature   : 35ºC 
Detector    : UV 220 nm 
Inj. Volume      : 20 µL  
Mobile Phase: Buffer   : Acetonitrile (9:16) 
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Preparation of acid solution: 
Measure 17 ml of Glacial acetic acid in 1000 ml standard volumetric flask and the 
volume is produced with distilled water. From this 100 ml solution was pipetted out in a 1000 
ml volumetric flask and the volume is made up using distilled water. 
Preparation of Buffer: 
Prepare 15 ml mixture of acetonitrile and triethylamine (1:1) and make upto 1000 ml 
with acid solution. Adjust the pH to 5.25 using ortho phosphoric acid. 
Diluent :   Acetonitrile and Acid solution (300:100) 
Mobile phase :   Acetinitrile and Buffer solution (432:768) 
Preparation of Standard Stock Solution: (0.25mg/ml) 
Weigh accurately 25mg of Fexofenadine Hydrochloride in a 100ml volumetric flask. 
Add 20 ml diluent and sonicate for 30mins then make upto the volume using diluent 
(Acetonitrile and Acid solution). 
Preparation Standard solution:  
Pipette out 5ml from the Standard stock solution in a 100ml volumetric flask and 
make upto the volume using mobile phase (Acetonitrile and Buffer solution) 
Preparation of Sample Stock Solution: (0.018mg/ml) 
Weigh accurately 180mg of crushed tablet (equivalent to 600 mg of fexofenadine 
Hydrochloride) in a 100ml volumetric flask. Add 20 ml Acid solution sonicate for about 
30mins. Then add 80 ml of Acetonitrile, and sonicate for about 60mins, dilute with diluent to 
volum, and filter.  
Sample solution:  
Pipette out 5ml of filtrate in a 50ml volumetric flask and make upto the volume using 
diluents. From this 5ml was pipetted out in a 50ml volumetric flask and make upto the 
volume using mobile phase (Acetonitrile and buffer solution). 
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Procedure: 
1.5ml/min Sample is injected into the HPLC instrument and it is allowed to run for 10 
minutes and the schematic representation graph is plotted from the instrument. The area value 
was obtained from the graph and amount of drug present in the formulation was calculated 
using the following formula.  
Amount of drug present = sample area/standard area × standard weight/100 × 5/100        
×100/Sample weight × dilution factor × average weight of 
the tablet. 
 IN-VITRO DRUG RELEASE STUDIES:
 
In vitro test for drug release serve two important functions, however.  First, data from 
such tests are required as a guide to formulation during the development stage, prior to 
clinical testing. Second, in vitro testing is necessary to ensure batch-to-batch uniformity in 
the production of a proven dosage form. Digital tablet dissolution test apparatus with paddle 
is used for the invitro dissolution studies of tablets.    
Preparation of 0.001N Hydrochloric Acid Buffer: (Dissolution medium) 
Measure 8.5ml of hydrochloric acid in 1 liter volumetric flask and make up the 
volume using purified water. Pipette out 10 ml of the above solution in a 1 liter volumetric 
flask and make up the volume using purified water. 
Preparation of solution A (Buffer solution): 
Weigh accurately 1.0g of monobasic sodium phosphate, 0.5g of sodium perchlorate, 
and 0.3 ml of concentrated phosphoric acid in 300ml of water. 
Mobile phase :  Acetonitrile and Buffer solution (7:3). 
Preparation of standard solution: 
Weigh accurately 20mg of Fexofenadine Hydrochloride in a 100ml volumetric flask, 
add 5ml of methanol and sonicate for 15mins, and make upto volume with dissolution 
medium. 
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Procedure:  
The invitro dissolution test is carried out in 0.001N Hydrochloric acid using Digital 
tablet dissolution test apparatus. The Fexofenadine tablets are subjected to dissolution testing 
using rotating paddle apparatus with a speed of 50 rpm in 900ml of dissolution medium.  Six 
tablets were used in each test.  A temperature of 37±0.5C is maintained throughout the 
experiment. A graph is plotted using time (in X-axis) against percent drug release (in Y- 
axis). 
  Sample is injected into the HPLC instrument and it is allowed to run for 10 minutes 
and the schematic representation graph is plotted from the instrument. The area value was 
obtained from the graph and amount of drug released from the formulation calculated by the 
formula below   
Percentage of drug released = 
           
             
 
               
   
 
   
   
     
8.4. PROCEDURE FOR FILM COATING SOLUTION: 
Equipment specifications:  
      Coating technique   :  Pan coating 
      Capacity of pan    :  3kg 
      Size of pan   :  18 inch 
      Pan speed    :  18 rpm      
      Solvent system used   :  water (aqueous solvent base coating) 
      Air pressure    :  1.0 bar 
      Nozzle size  :  1.0mm 
Table No: 14 Ingredients used for Film coating 
S.No INGREDIENTS QUANTITY FOR 200  TABLETS (in gm) 
1 Hypromellose E15 5.68 
2 Hypromellose E5 3.78 
3 Povidone  1.02 
4 Polyethylene glycol 400 7.88 
5 Titanium dioxide 4.20 
6 Colloidal silicon dioxide  1.46 
7 Iron oxide 0.03 
8 Purified water  176 ml 
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Preparation of coating solution: 
Specified quantity of hot water was added to Hypromellose E15 and using mechanical 
stirrer mixed it. Hypromellose E5 was mixed with colloidal silicon dioxide and added to the 
above mixture and mixed using mechnical stirrer for 10 or 15 minutes.  Povidone was added 
to the above mixture. Finally Titanium dioxide and iron oxide red were mixed separately with 
little quantity of water and added to the above mixture. This solution was used as coating 
solution for Fexofenadine hydrochloride. 
8.4.1. EVALUATION OF FEXOFENADINE HYDROCHLORIDE FILM COATED 
TABLETS: 
The film-coated tablets were evaluated for the following parameters weight variation 
test, disintegration, assay, invitro drug release studies and stability testing studies.   
8.5. STABILITY STUDY:
 46 
Fexofenadine Hydrochloride film coated tablets were packed in blister package and 
short-term stability studies were carried out in two different conditions (40
0
C/75% RH and 
30
0
C/65% RH). The film-coated tablets maintained at 40
0
C/75% RH were evaluated every 
month regularly. The tablets maintained at 30
0
C/65% RH were evaluated after three months. 
This short term stability studies were used for evaluating various parameters such as 
Description, Disintegration time, Assay, and drug release studies. 
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9. RESULTS AND DISCUSSION: 
9.1. PREFORMULATION STUDY: 
1. Appearance: white to off-white crystalline powder 
2. Solubility: 
Table No: 15 Solubility of Fexofenadine Hydrochloride 
S. No Solvents Solubility of Drug 
1. 1 Part in 5 part Methanol Freely soluble in methanol 
2. 1 Part in 10 part of Chloroform and water slightly soluble in chloroform and water 
3. Melting point: 142.5º C 
4. Loss on drying (%): 1.93% 
  PHYSICAL INCOMPATIBILITY STUDY: 
Table No: 16 Results of physical incompatibility Studies 
EXCIPIENTS USED INITIAL 
FINAL40ºC±2ºC/75 
%±5%RH(4 weeks) 
REMARKS 
Lactose monohydrate White powder No color change  It can be used in formulation 
Microcrystalline cellulose White powder No color change It can be used in formulation 
Croscarmellose sodium  White powder No color change It can be used in formulation 
Starch  White powder No color change It can be used in formulation 
Hypromellose E15 White powder No color change It can be used in formulation 
Hypromellose E5 White powder No color change It can be used in formulation 
Povidone  White powder No color change It can be used in formulation 
Polyethylene glycol  400 White powder No color change It can be used in formulation 
Titanium Dioxide White powder No color change It can be used in formulation 
Magnesium stearate White powder No color change It can be used in formulation 
Colloidal silicon dioxide  White powder No color change It can be used in formulation 
Pregelatinized Starch White powder No color change It can be used in formulation 
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CHEMICAL INCOMPATIBILITY STUDY: 
Table No: 17 Results of chemical incompatibility studies 
Wave Number (cm
-1
) Functional Group 
2960-2850 C-H Streching (alkane) 
1700-1725 C=O Streching (acid) 
1200-1500 O-H Bending (alcohol) 
1500-1700 N-H Bendig 
FTIR SPECTRAL STUDIES FOR API AND EXCIPIENTS 
Fig No: 1 FTIR Spectrum of Fexofenadine Hydrochloride 
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Fig No: 2 FTIR Spectrum Of Fexofenadine Hyddrochloride+ microcrystalline  cellulose 
 
Fig No: 3 FTIR Spectrum Of  Fexofenadine Hyddrochloride+Pregelatinised starch 
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  Fig No: 4 FTIR Spectrum Of  Fexofenadine Hyddrochloride+ Croscarmellose sodium 
 
Fig.no. 5 FTIR spectrum of Fexofenadine Hyddrochloride+ colloidal silicon dioxide 
 
  
RESULTS AND DISCUSSION 
 
 Page 73 
           Fig No: 6 FTIR Spectrum Of  Fexofenadine Hyddrochloride+magnesium stearate 
 
Fig No: 7 FTIR Spectrum Of  Fexofenadine Hyddrochloride+ Povidone  
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Fig No: 8 FTIR Spectrum Of  Fexofenadine Hyddrochloride+ entire all excipients 
 
9.2. PRECOMPRESSION STUDY: 
Table no: 18 Results of precompression studies 
S. No Formulation 
code 
Bulk 
density(g/ml) 
Tapped 
density(g/ml) 
Carr’s 
index (%) 
Hausner’s 
ratio (%) 
Moisture 
content (%) 
1 F-1 0.546 0.643 15.08 1.17 2.79 
2 F-2 0.513 0.604 15.06 1.17 2.26 
3 F-3 0.536 0.608 11.84 1.13 1.38 
4 F-4 0.443 0.513 13.64 1.15 3.59 
5 F-5 0.490 0.561 12.65 1.14 2.77 
6 F-6 0.478 0.549 12.93 1.14 2.76 
7 F-7 0.421 0.492 14.43 1.16 3.80 
8 F-8 0.529 0.599 11.68 1.13 4.16 
9 F-9 0.557 0.627 11.16 1.12 3.68 
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POST COMPRESSION STUDY: 
Table No: 19 Results of post compression studies 
Formula
tion code 
Thickness 
(mm) 
Hardness 
(Kg/cm
2
) 
Friabil
ity (%) 
Average 
Weight 
variation(mg) 
Disintegration Time 
Time in seconds 
With disc Without disc 
F-1 5.72±0.01 11.5±0.08 0.28 598.8±1.01 121±1.2 218±1.32 
F-2 5.76±0.03 11.25±0.1 0.22 599.61±1.12 119±1.1 131±1.26 
F-3 5.76±0.03 11.42±0.2 0.21 601.10±0.24 99±1.2 102±1.76 
F-4 5.80±0.04 10.5±0.42 0.26 599.98±1.02 33±1.3 35±1.36 
F-5 5.72±0.06 10.5±0.35 0.15 602.25±1.01 37±1.5 41±2.67 
F-6 5.78±0.02 9.55±0.22 0.18 600.20±1.07 34±1.5 35±2.2 
F-7 5.74±0.04 10.5±0.05 0.10 600.16±2.22 48±1.47 35±1.21 
F-8 5.77±0.03 9.50±0.28 0.18 600.5±1.46 31±2.13 28±1.13 
F-9 5.71±0.06 9.50±0.3 0.12 599.1±1.28 38±1.15 30±1.72 
The Average weight, Thickness, Hardness values are expressed as mean  ± SD n=5. 
The disintegration mean ±SD n=6 
Fig No: 9 Comparison of Thickness for formulation of F1-F9 
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Fig No: 10 Comparison of Hardness for formulation of F1-F9 
 
Fig No: 11 Comparison of Friability for formulation of F1-F9 
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Fig No: 12 Comparison of Disintegration Time for formulation of F1-F9 
 
9.4. ASSAY: 
HPLC CHROMATOGRAM FOR ASSAY 
Fig No:13   Assay Blank chromatogram 
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Fig No: 14  Assay standard chromatogram 
 
Fig No:15 Assay Sample chromatogram 
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ASSAY OF FEXOFENADINE HYDROCHLORIDE UNCOATED TABLETS: 
Table No: 20 Assay of fexofenadine hydrochloride uncoated tablets 
S. No Formulation code Assay (%) 
1 F-1 98.77 
2 F-2 99.33 
3 F-3 99.25 
4 F-4 100.06 
5 F-5 100.56 
6 F-6 99.05 
7 F-7 99.98 
8 F-8 100.68 
9 F-9 100.78 
9.5. DISSOLUTION STUDY 
HPLC CHROMATOGRAM FOR DISSOLUTION: 
Fig No: 16  Dissolution Blank chromatogram 
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Fig No: 17  Dissolution  Standard Chromatogram 
 
Fig No:18 Sample chromatogram dissolution 10min 
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Fig No: 19 Sample chromatogram 30min 
 
IN-VITRO DISSOLUTION OF FEXOFANADINE HYDROCHLORIDE UNCOATED 
TABLET -180mg 
Table No: 21 In-vitro dissolution of fexofanadine hydrochloride uncoated tablet -180mg 
S. No Formulation code % of Drug release 
10 minutes 30 minutes 
1 F1 69.28 75.67 
2 F2 61.08 76.38 
3 F3 67.66 80.32 
4 F4 68.59 85.56 
5 F5 74.95 85.08 
6 F6 70.70 85.14 
7 F7 81.37 86.07 
8 F8 89.77 91.81 
9 F9 91.52 96.25 
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Fig No: 20 Comparison of Dissolution profile of F1-f9 
 
 
Fig No: 21 Comparison of Dissolution profile of F1-F3 
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Fig No: 22 Comparison of Dissolution profile of F4-F6 
 
Fig No: 23 Comparison of Dissolution profile of F7-F9 
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INNOVATOR CHARACTERIZATION: 
Name              :  Fexofenadine Hydrochloride Tablet 180mg 
Brand Name :  Allegra 
Lot No            :  1138211 
Table No: 22 
TEST PARAMETERS RESULTS 
Description Oval shaped film coated tablet. Orange(peach)  colour 
Average weight 653mg 
Hardness 11 - 12 Kg/cm
2
 
Thickness 5.80mm 
Disintegration 1’.23’’(1 minute and 23 seconds) 
Assay(% label claim) 100 
In-vitro Dissolution study Percentage of drug release (%) 
10 minutes 30 minutes 
76.02 87.97 
EVALUATION OF FEXOFENADINE HYDROCHLORIDE FILM COATED 
TABLETS 
Table No: 23 Evaluation of fexofenadine hydrochloride film 
Coated tablets 
F. 
Code 
Thickness 
(mm) 
Hardness 
(kg/cm
2
) 
Weigh 
variation 
(mg) 
Disintegration 
Time (sec) Assay 
(%) 
% of Drug Release  
(Time in minutes) 
With 
disc 
Withou
t disc 
10 30 
F-9C 5.91±0.13 9.60±0.04 611.89±0.07 48±1.2 39±1.02 100.1
3 
91.06 95.25 
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COMPARISON OF UNCOATED AND FILM COATED FEXOFENADINE   
HYDROCHLORIDE TABLETS: 
Table No: 24  Comparison of uncoated and film coated fexofenadine 
Hydrochloride tablets: 
F- code 
Thicknes
s (mm) 
Hardness 
(kg/cm
2
) 
Weight 
variation 
(mg) 
Disintegration 
Time (sec) Assay 
(%) 
% of Drug 
release 
With 
disc 
Without 
disc 
10 30 
F-9 
(Uncoated) 
5.71±0.06 9.5±0.3 
599.1 
±1.28 
38±1.15 30±1.72 100.7 91.52 96.25 
F-9 
(Coated) 
5.91±0.13 9.6±0.04 
611.8 
±0.07 
48±1.2 39±1.02 100.1 91.06 95.25 
 
COMPARISON OF DRUG RELEASEOF INNOVATOR PRODUCT WITH F9 (UNCOATED) 
AND F9 (FILM COATED) TABLET  
Table No: 25 Comparison of drug release of innovator product with f9 (uncoated) and f9  
(film coated) tablet 
S. No. PRODUCT 
% Drug release 
10 minutes 30 minutes 
1 INNOVATOR PRODUCT 76.02 87.97 
2 F9 (Uncoated) 91.52 96.25 
3 F9 (Coated) 91.06 95.25 
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Fig No: 23 Comparison of Dissolution profile of ideal formulation with F9 film coated 
and  Innovator product 
 
RESULTS OF  STABILITY STUDIES OF F9 FILM COATED TABLETS: 
Table No: 26 Results of after stability studies 
PARAMETERS 
STORAGE CONDITION 
40
0
C±2ºC/75%±5%RH 
30
0
C±2ºC/ 
65%±5%RH 
INITIAL 
PERIOD 
ONE 
MONTH 
TWO 
MONTHS 
THREE 
MONTHS 
THREE 
MONTHS 
Description 
Orange 
(peach), Oval 
shape tablet 
No 
change 
No change No change No change 
Average weight(mg) 
611.89 
±0.07 
613.05 
±0.08 
613.06 
±0.06 
615.03 
±0.05 
613.07 
±0.02 
DT 
time 
(in sec) 
with disc 48±1.2 58±1.2 62±1.09 83±1.7 59±1.6 
with out 
disc 
39±1.02 46±1.07 59±2.01 70±1.9 56±1.09 
% of 
drug 
release 
10 mins 91.52 89.53 88.97 88.76 91.12 
30 mins 96.25 94.60 94.58 93.42 95.92 
Assay (%) 100.13 98.74 98.71 98.66 99.64 
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DISCUSSION 
Fexofenadine Hydrochloride tablets were formulated by wet granulation method. The prepared 
uncoated and coated (film) Fexofenadine Hydrochloride tablets were evaluated for the following 
parameters which includes Hardness, Thickness, Friability, Weight variation test, disintegration test, 
Assay and invitro drug release studies. 
Drug Excipients-Compatibility study: 
Preformulation compatibility studies were carried out before the formulation. There was no colour 
change in any of the samples. 
The FTIR spectrum of Fexofenadine Hydrochloride shows the presence of peaks at 2934.4 cm
-1
 of C-
H stretching (alkane), 1705.4 cm
-1 
of  C=O stretching (acid), 1223.2 cm
-1 
of  O-H bending (alcohol), 
and 1552.4 cm
-1  
of  N-H group  respectively.  
The FT-IR spectrum of the combined Fexofenadine Hydrochloride and Microcrystalline cellulose, 
Pregelatinised starch, Croscarmellose sodium, Colloidal silicon dioxide, and Magnesium stearate 
shows the presence of peaks at 2922.0 to 2955.6 cm
-1
 of C-H stretching, 1705.1 to 1705.9 cm
-1 
of  
C=O stretching, 1224.3 cm
-1 
of  O-H bending, and 1534.4 to 1577.9 cm
-1  
of  N-H group  respectively. 
All the peaks are indicating no interaction between drug and the excipients. 
Evaluation of Fexofenadine Hydrochloride granules: 
The bulk densities of all formulation were between 0.421 to 0.557 g/ml. The tapped densities of all 
formulations were between 0.492 to 0.643 g/ml. The Carr’s index values ranged from 11.16 to 
15.08%. The Hausner’s ratio of all formulations ranged from 1.12 to 1.17%. which showed good flow 
properties. 
Tablet characteristics of Fexofenadine Hydrochloride: 
Weight variation test: 
The weights of the tablets were between 598.8 to 602.25 mg. As the weight of the tablets was 600mg; 
the acceptable weight variation range is ±5%. As all the tablets meet the official specifications, all the 
formulations passed the weight variation test. 
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Thickness and Hardness test: 
Thickness of all the formulations was found to be between 5.71 to 5.80 mm respectively and the 
hardness of all formulations was in the range of 9.5 to 11.5 kg/cm
2
 respectively. 
Friability test: 
The friability values of all formulations  was between 0.12 to 0. 28 %, Friability test of all the 
formulation was found to be within prescribed limits. The results of friability test indicate that the 
tablets were mechanically stable and could handle the rigors of transportation and handling. 
Disintegration test: 
Further tablets were subjected for the disintegration test. Disintegration time for all  formulations 
rangedfrom28  to 218  sec. The disintegration time depends on disintegrating agent, method of 
addition of disintegrant, binder type, it’s concentration and force of compression. The formulation 
(F1-F3) which had starch and lactose showed higher disintegration time compared with the other 
trials. All the tablets disintegrated within 5 minutes, as all the formulations have super disintegrant 
between 2-6 %. 
Assay: 
In all formulations the content of drug were found to be within USP limit (NLT 95.0% and NMT 
105.0%).  
In-Vitro Dissolution Studies: 
 The cumulative amount of drug release from all the formulations were found to be 75.67%- 96.25% 
at the end of 30minutes. 
While comparing F1, F2 and F3 it has been observed formulation containing different concentration 
of excipients was used.  
 Formulation F1 which has starch (22%), povidone as binder and microcrystalline cellulose (42.66%) 
as intragranular disintegrant shows cumulative drug release of 75.67% and increased disintegration 
time. 
Formulation F2 which has Starch (20%), Povidone and microcrystalline cellulose (45.83%), has a 
drug release 76.38% which was same as  F1 formulation. The poor release could be attributed to 
higher binding which is also indicated by the higher disintegration time. 
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 Formulation F3 which has lactose monohydrate (30%) and microcrystalline cellulose (24%& 12%) 
The lactose monohydrate was added intra granularly and microcrystalline cellulose was added both 
intra and extra granularly, which showed increase cumulative drug release of80.32%when compared 
with F1and F2 formulation. 
While comparing the release profile of the formulation F4, F5, and F6 it has been observed that all the 
formulations released above 85% of drug at end of 30 minutes. 
Formulation F4 which has microcrystalline cellulose (13% and 20.25%) added both intra and extra 
granularly and pregelatinised starch (30%) was added intra granularly.  
 Formulation F5 which has microcrystalline cellulose (20.25%) added intra granularly, 
microcrystalline cellulose pH 102 (12%) was added extra granularly and pregelatinised starch (30%), 
was added intra granularly. 
Formulation F6 which has microcrystalline cellulose (20.25%) added intra granularly and 
pregelatinised starch (30% and 12%) was added both intra and extra granularly. 
The extra granular addition of the disintegrants has shown faster disintegration time and good 
dissolution profiles. 
Formulation F7 which has  microcrystalline cellulose (36.66%)added intra granularly, 
microcrystalline cellulose pH102 (5%) added extra granularly, and pregelatinised starch (5% and 
13%)added both intra and extra granularly showed a drug release was observed 86.07% at end of 30 
minutes. 
Formulation F8 which has microcrystalline cellulose (20%) added intra granularly, Microcrystalline 
cellulose pH 102 (11.66%) added extra granularly and pregelatinised starch (20% and 8.3%) was 
added both intra and extra granularly increased the drug release to91.81% at end of 30 minutes. 
In Formulation F9 dissolution profile was improved which has the same concentration of excipients 
when compared with F8. Only difference being the processing of granules. The granules were dried 
using a fluidized bed drier in this formulation. 
FormulationF1- F9 have been evaluated with respect to hardness, disintegration time, drug release 
studies, assay and other tests. Based on the above parameters, the trial number F9 showed good results 
and also it was found to be matching with the innovator product. Considering the above results of F9 
it has been selected for further film coating process. 
RESULTS AND DISCUSSION 
 
 Page 90 
Fexofenadine hydrochloride tablet of the above trial (F9) which satisfied all the parameters was 
coated using Hydroxypropyl methylcellulose as film polymer in aqueous based solvent by pan coating 
method. The coated tablets were evaluated for the following parameters including thickness, hardness, 
weight variation test, disintegration test, and assay and drug release studies. 
Comparison study with Innovator product: 
The in-vitro dissolution profile of Fexofenadine Hydrochloride batch (F9) was compared with 
Innovator product. The drug release of formulation (F9) was found to be 91.52 and 96.25 at 10 and 30 
minutes respectively. The drug release of innovator product was found to be 76.02 and 87.97 at 10 
and 30 minutes respectively. The uncoated tablets shows better release than the innovator product. 
After coating: 
All the parameters in the evaluation of uncoated tablets were carried out expect friability test for film 
coated trial (F9C). An increase in 3% weight was observed in film coated tablets when compare to 
uncoated tablets. The release of film-coated tablets were decreased than uncoated tablets. 
Stability studies: The film coated tablet of Fexofenadine Hydrochloride was kept for stability studies 
at 40
0
C±2ºC/75%±5% RH and at 30
0
C±2ºC/65%±5% RH. 
 At 40
0
C±2ºC/75%±5% RH, after 3 month  period no physical changes were observed. But 
disintegration time slightly increased. Dissolution and assay datas showed slight variation during 
stability studies. The three month of accelerated condition results were found to be satisfactory. The 
results at 30
0
C/65% RH after three months showed a slight increase in  disintegration time and no 
significant changes were observed in assay and drug release studies.  
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10. CONCLUSION 
Fexofenadine hydrochloride is a H1 receptor antagonist and used in urticaria and 
rhinitis. It is available in market as film coated tablet forms having poor release drug profiles. 
In this study it was tried to formulate fexofenadine hydrochloride film coated tablet by wet 
granulation, to improve the drug release profiles. 
A total of nine trials of fexofenadine hydrochloride tablets were formulated  by wet 
granulation  method. All the trials were evaluated for pre compression and post compression 
characteristics. 
Based on the preliminary studies various formulation trials (F1-F9) were carried out with 
different concentration of diluents, disintegrants, and binder. From the various formulations, 
the formulation F9 was finalized as the ideal formula, based on the different parameters 
which were compared with innovator, which proved to be successful. So it was planned to 
develop a new fexofenadine hydrochloride film coated tablet  by using hydroxypropyl 
methylcellulose film polymer in aqueous based solvent system and this coated formulation 
was evaluated for disintegration test, assay, drug release studies and short term stability 
studies. When subjected to accelerated stability studies the tablet were found to be stable. 
             Hence stable tablets with an improved  drug dissolution profile were suceesfully 
formulated. 
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